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CHAPTER 1 
Introduction 
1. Non-Hodgkin's Lymphomas. 
1.1 CLINICAL AND PHENOTYPICAL ASPECTS OF NON-HODGKIN'S LYMPHOMAS. 
Non-Hodgkin's lymphomas (NHL) represent a diverse group of clinical and pathological 
tumors and are the most common hematological malignancies in Europe and the USA 
(1,2). In the Netherlands approximately 1800 patients are affected each year (2). NHL 
may originate in B- or T- lymphocytes but are usually B-Iymphocytes (3.4). The NHL 
cells contain the phenotypic properties of the normal cellular counterparts with respect 
to the type (8- or T - lymphocytes) and their differentiation stage. The similarities 
between NHL cells and normal lymphocytes are the basis for the immunophenotypical 
classification of NHL, e.g., the Kiel classification (5). 
Follicular NHL, one subtype of NHL, accounts for approximately 20% of all NHL and is 
subject of investigation in this thesis (2). Follicular NHL is a B-cell malignancy and 
consists of monoclonal B-Iymphocytes. The cell types of follicular NHL resemble the 
cells in the secondary germinal center of lymph nodes and tonsils, small cleaved cells 
(centrocytes) and large cells (centroblasts) (4,5). The neoplastic cells preferentially 
home to the germinal centers and may show the same follicular structure. The structure 
in follicular NHL and normal tonsils is maintained by dendritic reticulum cells. Loss of 
these cells in follicular NHL may lead to a more diffuse growth pattern and 
transformation to a more malignant NHL (for review see 6,7). Follicular NHL has a 
relatively indolent course of disease and is therefore classified as low grade malignant 
NHL. It is seen predominantly in patients aged above 55 years (1). At diagnosis, only 
10% to 20% of the patients present with stage I or stage II disease (8), which means 
that the disease is localized to one or two lymph node(s) stations either above or below 
the diaphragm. These patients are usually treated by involved field radiotherapy alone, 
resulting in longstanding clinical complete remissions and even cure (9-11). Most 
patients (80% to 90%) present with disseminated disease (stages III and IV). The 
disease can then be detected in lymph nodes, peripheral blood, bone marrow or other 
organs. These patients are either treated with mild chemotherapy immediately at 
diagnosis or treatment may be postponed until disease progression ("wait and watch") 
(12,13). Although most patients initially respond to therapy, at some point the disease 
will relapse and in the end, usually several years after diagnosis, most patients do 
succumb from the disease. In patients with follicular NHL, accurate staging at diagnosis 
and the detection of small numbers of NHL cells during and after treatment may be 
important in the therapeutic management of the disease. In particular when new 
methods to detect minimal (residual) disease become available. A variety of methods to 
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detect malignant cells exists and will be discussed in more detail in section 3 paragraph 
1 of this chapter. 
1.2 TRANSLOCAT10NS IN NON~HODGKIN'S LYMPHOMAS. 
Numerous hematologic malignancies are characterized by chromosomal abnormalities 
(for review see 14). The most common chromosomal translocations in 8-cell NHL are 
the t(14;18)(q32;q21) which activates the B-cell lymphoma-2 (BCL-2) oncogene, and 
the t(8;14)(q24;q32) in which c-MYC is the target gene (7,14). Less common 14q32-
associated translocations are t(2;14)(p13;q32) (15). t(3;14)(q27;q32) (16) 
t(10;14)(q24;q32) (17), t(11 ;14)(q13;q32) (18,19), t(14;17)(q32;q23), 
t(14;19)(q32;q13) (20) and t(14;22)(q32;q11). Other chromosomal translocations are 
t(2;5)(p23;q35) (21). t(2;18)(p12;q21) (22,23). t(3;22)(q27;q11) (24,25) and 
t(2;3)(p12;q27) (16). Identified genes which are found in these translocations ~ill be 
presented in Table 1 section 3 paragraph 2. 
One of the most common chromosomal translocations in B-cell NHL, the 
t(14;18)(q32;q21). is typically associated with follicular NHL and the subject of 
investigation in this thesis. The translocation is found in 60% to 85% of these NHL 
(26-32). The incidence of t(14;18) in follicular NHL is dependent on the technique used. 
The detection of t(14;18) is enhanced, in comparison to polymerase chain reaction 
(PCR) and cytogenetic analysis, by pulsed-field gel electrophoresis (32). The t(14;18) is 
also found in 20% to 30% of diffuse large cell NHL (33,34). Thus, t(14;18) may be 
used as a marker in follicular and diffuse large cell NHL. The molecular organization of 
the chromosomal translocation and the function of the BCL-2 gene have been subject 
of intensive research in recent years. This will be discussed in more detail in the section 
2 of this chapter. 
2. The chromosome translocation t(14;18). 
2.1 THE BCL-2 GENE AND ENCODED PROTEINS. 
The BCL-2 gene, involved in the chromosomal translocation t(14;18). is located on 
chromosome 18 band q21 and has a'three exon structure (Figure 1: chromosome 18). 
The first exon is not translated (35). The relatively large intron 2 exists of 225 
kilobases (kb)(36). Three BCL-2 transcripts, 3.5, 5.5 and 8.5 kb long, have been 
identified (37). All transcripts contain exon 2 sequences, but the 5.5 and 8.5 kb 
transcripts contain also exon 3 sequences. These last two transcripts use different 
polyadenylation sites. 
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Two BCL-2 protein products have been identified, the 26 kilodalton (kOa) BCL-2a 
derived from the 8.5 or 5.5 kb transcripts and the 22 kOa BCL-213 derived from the 3.5 
kb transcript (37,38). These proteins differ in their carboxy terminus as a result of 
alternative splice site selection (37,38). The 26 kOa BCL-2a protein has a hydrophobic 
carboxy terminal membrane spanning -domain and is located in the outer mitochondrial 
membrane (39). The 22 kOa BCL-213 protein lacks the hydrophobic membrane spanning 
domain and is therefore not membrane associated, (40). 
2.2 THE IMMUNOGLOBULIN HEAVY CHAIN GENE. 
During differentiation of the hematopoietic stem cell into a B-Iymphocyte, the 
immunoglobulin genes rearrange in an ordered manner. The rearrangement of the 
different segments of the immunoglobulin heavy (lgH) chain gene occurs first (41-45). 
The .lgH gene is located on chromosome 14 (q32) (Figure 1: chromosome 14). 
Rearrangement of different segments of this gene may result in a functional heavy 
chain of the immunoglobulin. Antigen variability is created following the assembly of 
the variable (V), the diversity (D) and joining (J) segments of the IgH gene and the 
addition of several bases during this assembly (46,47). There are 100 to 200 V 
segments clustered in 7 families (48-50), at least 24 D segments clustered in 9 families 
(51-54) and 6 J segments (55). The first event of the IgH rearrangement is the O-J 
joining and subsequently the joining of one V segment to this complex. These 
rearrangement processes are mediated by a sequence specific recombination 
mechanism (56). The constant (C) region segments of the IgH gene are located 
downstream of the J segment and encode five different immunoglobulin classes (lgM, 
IgO. IgG, IgA and IgEI. Upstream of most C segments a switch (5) segment is found, 
which plays a role in a late event in the generation of a functional IgH molecule, the 
class switch (57,58). The IgH gene is involved in the t(14;18). 
2.3 MOLECULAR CHARACTERISTICS OF THE TRANSLOCATION T(14;18). 
In the translocation t(14;18), either the J or 0 segment of the IgH gene (14q32) is 
juxtaposed to the BCL-2 gene (18q21) (26,30,31,59-61) (Figure 1: translocation 
t(14;18)). This places BCL-2 in the same transcriptional orientation as the IgH locus. 
Breakpoints on chromosome 14 are usually located just 5' of one of the J segments, 
predominantly J3-J6 (62). Two breakpoint clusters have been identified within the BCL-
2 gene, the major breakpoint region (mbr) spanning 150 base pairs (bp) (30,31,60,63) 
and the minor cluster region (mcr) spanning 500 bp (64-66). The molecular 
characteristics of both the mbr and mer translocations allow the application of the 
highly sensitive and specific polymerase chain reaction, PCR, an in vitro DNA 
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amplification technique (63,66,67, chapters 2, 3 and 4). The size of the t(14;18) 
specific peR fragments depend on the localization of the breakpoints on chromosomes 
14 and 18. Therefore, the size of these fragments are usually different in individual 
patients. The majority (60% to 70%) of the breakpoints are in the mbr, located in the 
non-coding region of exon 3. 20% to 30% of the breakpoints are located in the mer, at 
least 20 kb downstream from the mbr and outside the BCL-2 gene (64,66). In a 
minority of the patients the breakpoint is located 5' of the BCL-2 gene (64). 
Figure 1: 
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... ... 
5' 
--Ea I 3' 
exon 2 exon 3 
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s 
s· 3' 
exon 2 exon 3 
Schematical representation of the genomic organization of the 
chromosomes 14, 18 and the translocation t(14;18). The variable (V), 
diversity (0), joining (J), switch (S) and constant (C) segments of the 
immunoglobulin heavy chain gene are located on chromosome 14. The 
oncogene BCL~2 is located on chromosome 18. The two coding exons (2 
and 3) and the breakpoint regions (mbr and mcr) are designated. The 
breakpoints of the t(14;18) are in this figure located just 5' of the JH5 
segment and in the mbr of the BCL-2 gene (not drawn at scale). 
2.4 POSSIBLE RECOMBINATION MECHANISMS IN THE TRANSLOCATION T(14;18). 
The clustering of the breakpoints, especially in the mbr, suggests a sequence specific 
recombination mechanism. Heptamer I spacer I nona mer recognition sequences are 
involved in the recombination of the VOJ or VJ segments of the IgH and T-cell receptor 
genes (56). Such sequences have also been reported to be located near the mbr of the 
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BCL-2 gene, although there are some sequence differences (68). These recombination 
signals can account for the aberrant joining of the BCL-2 gene to one of the J 
segments. Therefore, t(14;18) is thought to occur as a mistake in VOJ joining (68). 
2.5 FUNCTION OF BCL-2. 
The translocation t(14;181 places the BCL-2 gene under control of IgH regulatory 
sequences, inducing high expression levels of the_ BCL-2-lg fusion RNA (35,64,69,70) 
and the normal 26 kDa BCL-2a protein (70). The function of BCL-2 has been elucidated 
in part by hematopoietic cell lines studies. BCL-2 cDNA has been transfected into 
interleukin-2 (IL-2), IL-3, IL-4, IL-6 and granulocyte/macrophage colony-stimulating 
factor (GM-CSF) dependent hematopoietic cell lines (71-73). Deprivation of the 
essential growth factor normally induces programmed cell death (apoptosis) in these 
growth factor dependent cell lines. In cell lines transfected with BCL-2, enhanced cell 
survival has been reported, i.e., prevention of programmed cell death following 
withdrawal of IL-3, IL-4 and GM-CSF. In an IL-3 dependent multi potent hematopoietic 
cell line this increased cell survival is accompanied by multilineage differentiation in the 
absence of IL-3 (73). The capacity of BCL-2 to inhibit cell death has also been reported 
for gamma irradiation induced apoptosis. Gamma irradiation causes the production of 
oxygen free radicals (39). Oxygen free radicals induce damage to DNA, proteins and 
lipids (39). BCL-2 functions in an antioxidant pathway to prevent cellular damage, 
especially damage caused by lipid peroxidation (39). 
The BCL-2 gene is the first described oncogene which interferes with programmed cell 
death in mammalian cells. Recently, several genes with BCL-2 related sequences have 
been identified (74-79). One of those genes, the BCL-x gene has a role in both positive 
and negative regulation of apoptosis in a growth factor dependent cell line. Two protein 
products of this gene BCL-Xs and BCL-xi with opposite functions have been identified 
(75,76). BCL-xi is similar in size, structure and function to BCL-2. SCL-x~ differs from 
BCL-xi because it lacks the sequences that display greatest similarity between BCL-xi 
and BCL-2. BCl-x" encodes a protein that inhibits the ability of SCl-2 to prevent 
apoptosis. Also a gene of a BCL-2 associated protein, Bax, has been identified (75,77). 
The 21 kDa Sax protein shows extensive amino acid homology with BCL-2. 
Overexpression of Sax neutralizes BCL-2 and accelerates apoptotic cell death induced 
by IL-3 deprivation in a IL-3 dependent cell line (75;77). 
Functional aspects of BCL-2 gene expression have also been studied in transgenic mice. 
The BCL-2-lg fusion gene of the chromosomal translocation t(14;18) has been used to 
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create BCL-2-lg transgenic mice and the effect of t(14;18) was studied during 
development. Transgenic mice showing overproduction of BCL-2 had a long-term 
persistence of immunoglobulin secreting cells and an extended lifetime of memory B-
ceUs (80). These transgenic mice developed lymphadenopathies infiltrated with 
polyclonal mature B cells (81). After a long latency period progression from a polyclonal 
to a monoclonal 8-cell population and transformation to clinical lymphoma was 
apparent in these transgenic mice (82). Progression towards the malignant NHL was 
associated with additional c-myc rearrangements (82,83). 
Despite widespread embryonic expression of the BCL-2 protein, transgenic mice 
carrying two inactivated BCL-2 genes develop normally but display polycystic kidney 
disease and hypopigmented hair (84,85). Lymphocyte differentiation is initially normal, 
but no stable immune system is generated after birth (84,85). The presence of 
polycystic kidney disease and hypopigmentation of hair in these mice, pathologies 
which are probably related the redox state of cells, is in concordance with the role for 
BCL-2 in an antioxidant pathway (39,85). 
2.6 BCL-2 PROTEIN EXPRESSION IN NON-HODGKIN'S LYMPHOMAS. 
Expression of BCL-2 protein has been reported in normal lymphoid cells and a variety of 
Iymphoproliferative disorders (70,86). The BCL-2 protein has been demonstrated in 
precursor cells of all hematopoietic lineages, activated- and memory- B-cells, and 
plasma- and mantle zone- B-cells of follicle centers in human tonsils (70,86-89). In the 
follicle centers of human tonsils the BCL-2 protein could not be demonstrated 
(70,87,90 chapter 3). In follicular NHL carrying the t(14;18), the BCL-2 protein is 
always found (70,90,91, chapter 3). In addition, in follicular NHL without the 
translocation an equally intense BCL-2 protein expression has been demonstrated 
(~0,92 chapter 3). In other histological subtypes of NHL, t(14;18) and BCL-2 protein 
expression may be present (70,87,93,94). In diffuse NHL t(14;18) may occur in 20% 
to 30% of the lymphomas (33,34). BCL-2 expression has been reported in a variable 
proportion (20% to 80%) of diffuse NHL and is not restricted to diffuse NHL carrying 
the t(14;18) (86,90,91,93). NHL of the gastro-intestinal tract, a neoplasm in which the 
t(14;18) occurs infrequently, may express the BCL-2 protein in 50% to 75% of the 
lymphomas (93,94). In lymphomas of mucosa-associated lymphoid tissue (MALT), 
presence of the BCL-2 protein and absence of t(14;18) has been reported (87). These 
findings suggest that there may be a role for BCL-2 in the development of NHL in 
general and follicular NHL in particular. 
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3. Detection of minimal (residual) disease. 
3.1 DIFFERENT METHODS FOR THE DETECTION OF MAUGNANT CELLS. 
Detection of small numbers of malignant cells is potentially useful for i) staging of the 
disease at initial diagnosis; ii) monitoring of the disease during and after therapy and iii) 
early detection of relapse. Minimal residual disease (MRD) is defined as the few 
malignant cells which have survived initial remission~induction chemotherapy (95). The 
persistence of these cells becomes apparent because they may cause relapse following 
variable intervals (95). There are several methods to detect small numbers of malignant 
cells in patients with hematological malignancies. The possibilities and limitations of 
methods to detect MRD depend on specificity (malignant cells have to be discriminated 
from normal cells) and sensitivity (detection limit). Many of the conventional 
techniques, such as morphological examination and immunological marker analysis are 
not specific for malignant cells and relatively insensitive. Certain cytogenetic and DNA 
techniques are highly specific but insufficiently sensitive. Recently, a new specific and 
sensitive DNA technique has been developed which may be used for the detection of 
MRD. Here, we summarize the methods that are currently used for the detection of 
minimal neoplastic disease: 
a) Detection of malignant cells by morphological examination is insensitive and not 
specific. In order to identify malignant cells, at least 5 % of the cell population 
must be morphologically distinguishable as malignant cells (961. Therefore, this 
method has limited value for the detection of MRD. 
b) Immunological marker analysis is more sensitive than morphological 
examination. Malignant lymphoid cells express the same markers as their normal 
counterparts. Expression of unusual immunological markers is rarely seen. 
Therefore, lymphoid cells positive for certain immunological markers or marker 
combinations may indicate malignancy either when these cells are present at a 
greater frequency than normal or when they are present outside their normal 
homing areas. Specificity is dependent on the choice of immunological markers. 
Demonstration of a monoclonal B-cell population by double fluorescent staining 
for both the immunoglobulin heavy and light chains may be used in NHL. With 
this method a sensitivity of 0.1-1 % can be reached (97,98, chapter 21. The 
greatest sensitivity of immunological marker analysis (0.01-0.001 %) has been 
demonstrated by double immunofluoresence staining in T-cell acute Iympoblastic 
leukemia using T-cell specific markers in combination with terminal 
deoxynucleotidyl transferase (TdTI (99,1001. The normal counterparts of these 
double positive cells are rare in bone marrow and peripheral blood (100). 
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Detection of double positive cells in peripheral blood or bone marrow in those 
diseases, in which the combination of markers is rare in normal conditions, 
provides a very sen~itive and specific method for the study of MRD. 
c) Cytogenetic analysis using banding techniques can detect chromosomal 
abnormalities unique of the malignancy (101). With this technique only a limited 
number of cells in metaphasis (usually less than 40) can be evaluated. Although 
this technique is highly specific for the malignancy, the small cell sample size 
which can be evaluated reduces the applicability of this technique for the 
detection of MRD (1011. 
d) Fluorescent in situ hybridization (FISH) techniques can be used to detect 
chromosomal abnormalities such as the t(9;221 (1021, the t(S;141 and t(14;1SI 
(103). the t(1 ;71 (1041 and translocations involving the chromosome 11 q23 
region (105). For t(9;22) two-colour FISH was carried out with probes specific 
for the Abelson oncogene of chromosome 9 and the BCR gene of chromosome 
22 (102,106,107). This technique is highly specific for the malignancy and it 
can be applied to all cells of a population. However, the sensitivity of this 
technique is limited by the number of cells which can be evaluated and the 
statistical chance of overlapping signals. 
e) Southern blot analysis can be used to detect chromosomal abnormalities, i.e. 
chromosomal translocations, and rearrangements of the antigen receptor genes 
of the B- and T- lymphocytes. Both chromosomal abnormalities and 
rearrangements of the antigen receptor genes are specific of the malignant 
clone. The sensitivity is about 5% (108-111). 
f) The PCR is a technique in which DNA sequences are amplified in vitro using 
specific synthetic oligonucleotides (67). With these oligonucleotides a DNA 
sequence is defined, unique and specific of the malignant cell population. For 
instance, the detection of the chromosomal breakpoint regions, i.e., the 
translocation t(14;18), and rearrangement of the antigen receptor gene, 
representing the malignant cells may be used for detection of minimal numbers 
of neoplastic cells (100). With this technique a detection limit of 1 malignant cell 
among 10'-10' normal cells has been reported (67,100). The specificitY and the 
sensitivity make this technique promising for the detection of MRD. 
g) Combining the high sensitivity of PCR with the cell localizing ability of in situ 
hybridization, in situ PCR, has been described for the detection of a variety of 
targets. Several RNA viruses and many human mRNAs have been detected using 
in situ reverse transcriptase mediated PCR (RT-PCR) (112,113). Application of 
this technique reveals that the frequency of virus infected mononuclear blood 
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cells is at least 10 times higher than previously described (112). This technique 
is also potentially promising for the detection of MRD. 
3.2 ApPLICABILITY OF peR IN HEMATOLOGICAL MALIGNANCIES. 
The chromosomal translocation t(9;22)(q34;qll), which is seen in 95% of patients 
with chronic myeloid leukemia (CML) and in 30% to 40% of the adult acute 
lymphoblastic leukemia (ALL) patients, has been extensively studied by cytogenetic 
analysis and recombinant DNA techniques (100,106,107). In this translocation the 5' 
sequences of a gene designated BCR are fused to the 3' sequences of the Abelson 
oncogene (106,107). The translocation t!9;22) (also designated as the Philadelphia (Ph) 
chromosome) is used to study MRD. CML patients have been studied for the presence 
of t(9;22) after allogeneic bone marrow transplantation. In the majority of these 
patients t(9;22) is not detectable by cytogenetic analysis but with RT-PCR the t(9;22) 
can be demonstrated (114-119). Most patients show PCR detectable t(9;22)-positive 
cells during the first 6 months after transplantation (114,115). peR-positivity for a 
longer period may indicate that these patients have not been cured (114-117). In T-cell 
depleted bone marrow transplantations more patients remain t(9;22) positive and this 
appears to correlate with the greater relapse frequency following T~cell modified 
transplants (115). In one study the t(9;22) has been demonstrated by PCR in 
approximately 55% of patients with adult common ALL. Detection of this translocation 
is correlated with remission duration and poor survival (116,118). The correlation 
between clinical outcome and PCR results compared to chromosomal analysis for 
t(9;22) is still under investigation (116). Chromosomal translocations which may be 
used as targets for PCR and for the study of MRD, are summarized in Table 1. Studies 
concerning the detection of MRD using PCR have been described for t(6;9) (121), 
t(8;21) (123-126), t(15;17) (130-132) and t(4;11)(q21;q23) (140,141). From these 
studies it is concluded that application of PCR in the in vitro amplification of the 
chromosomal breakpoint regions enhances the sensitivity by which MRD can be 
detected. 
In NHL, especially follicular NHL, the chromosomal translocation t(14;18) is generally 
considered as a marker 'for NHL cells. The breakpoint of this translocation has been 
used for PCR detection of MRD in NHL patients in several studies (63,66,142-145, 
Chapters 2, 3 and 4). It has become apparent that t(14;18) should be utilized with 
caution as a marker for residual NHL cells because t(14;18) may also be identified 
among non-malignant lymphoid cells. The occurrence of t(14;18) not related to any 
malignancy has been reported in approximately 50% of the benign lymphoid tissues 
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Table 1: Chromosomal translocations in myeloid and lymphoid malignancies used for detection of minimal residual disease with PCR. 
Chromosomal translocation Disease Genes Target References 
t(6;9)(p23;q34) acute myeloblastic leukemia DEK, CAN mRNA 14,120,121 
t(8;21 )(q22;q22) acute myeloid leukemia AML1, ETO mRNA 14,122-126 
1(9;22)(q34;q11 ) chronic myelocytic leukemia, acute BCR, ABL mRNA 14,106,107,114-119 
lymphoblastic leukemia 
t(15;17)(q22;q21) acute promyelocytic leukemia PML, RARa mRNA 14,127-132 
t(1 ;19)(q23;p13) pre-B acute lymphoblastic leukemia E2A, PBX1 mRNA 14,133-136 
1(2; 14)(p 13;q32) chronic lymphocytic leukemia REL,lgH DNA' 14,15 
t(2; 18)(p12;q21) chronic lymphocytic leukemia, non-Hodgkin's Ig kappa, BCL-2 DNA' 14,22,23 
lymphoma 
1(4; 11 )(q21 ;q23) childhood acute lymphoblastic leukemia MLL, AF-4 mRNA 14,137 
1(8; 14)(q24;q32) Burkitt's lymphoma MYC,lgH DNA' 14,138 
t(1 0; 14)(q24;q32) B-cel! non-Hodgkin's lymphoma LYT10,lgH mRNA 17 
1(11; 14)(q13;q32) mantle eel! lymphoma BCL-1, IgH DNA 14,139-142 
1(14; 18)(q32;q21) B-cel! non-Hodgkin's lymphoma IgH, BCL-2 DNA 14,63,66,143-146 
1(14; 19)(q32;q 13) chronic lymphocytic leukemia, non-Hodgkin's IgH, BCL-3 DNA' 14,120 
lymphoma 
--- --------------
. peR is possible if the breakpoint in each patient is cloned and characterized. 
with follicular hyperplasia (146,147). In these conditions the frequency of t(14;18)-
positive cells is extremely low and has been estimated at approximately one t(14;18)-
positive cell per 10' lymphoid cells (146,147). These t(14;18)-positive cells in non-
neoplastic tissue can be detected by peR only. In order to search for residual t(14;18)-
positive NHL cells and at the same time exclude the possibility that the t(14;18)-
positive cells are not related to lymphoma, one would at least need the diagnostic 
lymph node biopsy from the patient, prior to treatment, to confirm that the t(14;18)-
positive cells found in peripheral blood or bone marow are identical to the t( 14; 18)-
positive cells of the lymph node biopsy. Studies related to this issue are reported in 
chapters 3 and 4. 
In 20% to 30% of diffuse NHL the t(14;18) may also be used as a marker to study 
MRD. The study of MRD in diffuse NHL seems to be more clinical relevant than in 
follicular lymphoma. The reason for this is the cure rate of approximately 40% of the 
patients after conventional chemotherapy. For NHL and lymphoid malignancies lacking 
a characteristic translocation, the rearrangement of the antigen receptor genes may be 
used as a marker for the malignant cells. Rearrangement of the VOJ segments of the 
IgH gene and the addition of bases during the assembly, result in the generation of a 
highly specific and unique sequence for a single 8~lymphocyte clone (44-56, 148~157). 
4. Aim of the study. 
This study is concerned with the detection of small numbers of malignant cells in 8-cell 
NHL, especially follicular NHL, using the translocation t(14;18) as a target for peR. The 
possibilities of PCR in the detection of MRO are compared to those of other techniques 
(chapter 2). In chapters 3 and 4 t(14;18) has been used as marker for lymphoma cells. 
The clinical significance of the presence of residual t(14;18)-positive cells in peripheral 
blood and bone marrow has been studied in patients treated for localized and 
disseminated disease. The presence of t(14;18) and the 8CL~2 protein was investigated 
in a different subtype of NHL, i.e .. NHL with testicular localization (chapter 5). This has 
been studied in different subtypes of NHL, but had to our knowledge not been studied 
in NHL with testicular localization. Finally we have generated a new NHL cell line 
containing the chromosomal translocations t(8;14) and t(14;18). This cell line 
represents an addition to the few cell lines with the translocations t(8;14) and t(14;18) 
that are currently available (chapter 6). The availability of these cell lines may facilitate 
further studies aimed at the role of these translocations and thereby the absence of 
functional immunoglobulins in deregulating cell growth and maturation in NHL. 
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CHAPTER 2 
Detection of residual disease in translocation (14;18) 
positive non-Hodgkin's lymphoma, using the polymerase 
chain reaction: A comparison with conventional staging 
methods. 
A.C. Lambrechts, P.E. de Ruiter, L.C.J. Dorssers and M.B. van 't Veer. 
Leukemia 6: 29-34, 1992. 
Detection of Residual Disease in Translocation (14;18) Positive Non-Hodgkin's Lymphoma, Using 
the Polymerase Chain Reaction: A Comparison With Conventional Staging Methods 
A.C. Lambrechts\-P.E. de Ruiter" LC.J. Dorssers1, and M.B. van 't VeerZ 
IDepartment of Molecular Biology, and =Department of Haemato!ogy. Dr Daniel Den Hoed Cancer Center, Rotterdam. The Netherlands 
This paper reports the detection of residual lymphoma cells in 
blood and bone marrow samples from patients with transloca-
tion (t) (14;18) positive non-Hodgkin's lymphoma by the 
polymerase Chain reaction (peR) compared with conventional 
staging techniques. In 15 of 22 samples, in which no lymphoma 
cells could be detected by morphological examination, t(14;18) 
positive cells were detected by peR. In 13 of 21 samples, in 
which a monoclonal Socell population was not detectable by 
immunological marker analysis. PCR was positive. The clinical 
status (physical examination, imagIng techniques, leucocyte 
count, and occasionally morphology and immunological marker 
analysis) was documented in 30 patients at the time of peR 
analysis. In three of 19 patients with clinical evidence of 
disease, circulating t(14;18) positive cells were not detectable 
by peR. Five of 11 patients in clinical remission from 7 to 47 
months, showed t(14;18) positive cells in the blood. Our data 
show that peR analysis in t{14;18) positive non-Hodgkin's 
lymphoma offers a powerful tool in the study of resIdual 
disease. 
INTRODUCTION 
Non-Hodgkin's lymphoma (NHL), in contrast to leu-
kaemias, is a primary localized disease, which may 
secondarily spread to the-blood and bone marrow. For 
the detection of minimal disease at staging and after 
treatment, various complementary techniques, includ-
ing imaging of lymph nodes and detection of lymphoma 
cells in blood and bone marrow by morphology and 
immunological marker analysis, must be relied upon. 
The in vitro amplification of DNA sequences by the 
polymerase chain reaction (PCR) has opened new 
perspectives for a very sensitive detection of lymphoma 
cells. Target sequences that are unique for lymphoma 
cells are provided by chromosomal translocations and 
antigen receptor rearrangements. The reciprocal trans-
location between chromosomes 14 and 18 [t(14:18)1 is 
the most common chromosomal abnormality found in 
B-NHL. Although t(14;18) is seen in various histo-
logical subtypes of NHL, it predominates in lympho-
mas with a follicular growth pattern. Both cytogenetic 
and molecular studies report the occurrence of the 
t(14;18) in 50-80% of follicular NHL and in up to 30% 
of diffuse -NHL (1-5). In this translocation the joining 
(JH) segment of the immunoglobulin heavy chain 
(IGH) gene, located on the long ann of chromosome 
14 (band q32), is transferred to the BCL2 gene on the 
long ann of chromosome 18 (band q21) (6-10). This 
translocation ereates a DNA sequence which is unique 
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for the lymphoma cells: a hybrid BCL2/JH sequence 
(6,8,11,12). Two breakpoint clusters are identified 
within the BCL2 gene (13). The major breakpoint 
region (robr) is involved in 50-60% of the transloca-
tions and spans only 150 bases (8,10,14). The minor 
cluster region (mer) is found in 25-30% of the 
translocations and involves a breakpoint region of 500 
bases (1,13,15). In a minority of patients with t(14;18) 
positive lymphoma the breakpoint is located 5' of the 
BCL2 gene (16). The frequency of this translocation 
and the molecular characteristics of both the mbr and 
the mer allow the application of the PCR to detect 
lymphoma cells in a substantial number of NHL 
patients. 
Here we report the results of the PCR analysis of 
blood or bone marrow samples for the detection of 
residual lymphoma cells compared with morphology 
and immunological marker analysis in patients with 
clinical evidence of disease (CED) or in clinical 
complete remission (CCR). 
MATERIALS AND METHODS 
Patients 
Lymph node biopsies. blood and bone marrow samples from 79 
patients with NHL were collected at diagnosis or during and after 
treatment. Staging of the patients (17) was performed following 
standard procedures. including pbysical examination. cr scan of 
the thorax and abdomen, and morphological and immunological 
analyses of blood and bone marrow. The distribution of the 
different types of NHL according to the Working Formulation 
for NHL (18) [Kiel Classification (19)] was: 56 follicular mixed 
small and large cells [follicular centroblastic centrocytic (cb/cc)]. 
SL'I: diffuse mixed small and large cells (diffuse cb/cc). four diffuse 
small cleaved (diffuse cc). and two diffuse large cleaved cell 
(diffuse cb). eight smalilymphoplasmacytoid (immunocytoma). 
two lymphoblastic (lympboblastic). and one small lymphocytic 
(lymphocytic). The patients were treated, if the grade of 
malignancy of the lymphoma was low. with cyclophosphamide. 
vincristine and prednisone (CVP). and if the grade of malignancy 
was intermediate or high. with these cytostatic drugs combined 
with adriamycin (CHOP). 
DNA £xtraction 
Two portions of white blood cells were isolated from 20 m1 of 
heparinised blood or 2-5 ml of bone marrow using an erythro-
cyte lysis buffer (ISS ffiM NH;O. 10 ffiM KHC03• 1 rn.-.t EDTA. 
pH 7.4). and stored in liquid nitrogen. High molecular weight 
DNA was prepared from these isolates and from frozen lympb 
node biopsies and cells from the cell line SU-DHL·6 (a gift of 
Dr K. Tbie1emans) carrying a mbr t(14:18) (20). according to 
standard protocols (21.22). If frozen tissue was not available. 
DNA was isolated from paraffin embedded lymphoma biopsies. 
One 8 (J.m section was deparaffinated by xylene (2 x 5 min). 
washed with 96 and 70% ethanol. and dried. The section was 
resuspended in 100 p.l of water and heated to 9SoC for 10 min; 
1-10 p.l were used for amplification by PCR. 
Southern Blot Analysis 
Ten micrograms of chromosomal DNA, extracted from the 
lymph node biopsies on which the diagnosis was made. were 
digested with 20-30 U of the restriction enzyme Hindlll under 
the conditions recommended by the suppliers. DNA was size~ 
fractionated on 0.8% agarose gels and transferred to nylon 
membranes (Hybond N+ . .Aroersham). Hybridization was per-
formed according to standard procedures. using np-labeled 
DNA probes radiolabeled by the hexamer primer method (21). 
The following probes were used: a JH probe. specific for the 
joining regions (JH3-JH6) of the IGH gene (23), a BCL2 probe 
specific for the mbr-t(14:18). a gift of Dr Y. Tsujimoto (7). and 
the mcr-t(14;18). a gift of Dr M.L. Cleary (IS). 
Polymerase Chain Reaction 
For PCR analysis (24) of the mbr t(14:18). two primers were 
defined: a BCL2 primer (5'·GGTGGTITGACCTITAGA~3') 
and a JH consensus primer (S'·TGAGGAGACGGTGACC·3') 
(synthesized by Pharmacia Nederland. Woerden. The Nether· 
lands) (6.8.14.25.26). For the mer t(14:18) a BCL2 primer 
(S'·CAGTCTCTGGGGAGGA-3') was combined with the same 
JH primer (27). DNA (0.5 p.g) in a reaction volume of 25 p.l was 
subjected to a 30 cycle PCR amplification using an automatcd 
Perkin~Elmer/Cetus DNA Thermal Cycler. Taq DNA poly· 
merase (perkin·Elmer/Cetus Nederland, Gouda. The Nether· 
lands: 0.25 U: Promega Cooperation Leiden, The Netherlands: 
0.20 U) and the recommended buffer conditions. The optimum 
cycle conditions were: denaturing at 94°C for 7 min in the first 
cycle and 1 min for the 29 subsequent cycles. annealing at SSoC 
(mbr) or 56°C (mcr) for 2 min and extension for 2 min at 72°C. 
followed by a final extension of 7 min. 
One fifth of the amplified samples was analysed on a 1.2% 
agarose gel. followed by Southern blotting. Ethidium bromide 
staining occasionally showed a visible band. Hybridization with 
the corresponding BCL2 probe was often necessary to detect the 
amplified product. As a control to DNA quality. all samples were 
subjected to a 25 cycle PCR amplification of the interleukin·3 
(IL·3) gene (primers: 5'·GAGGTTCCATGTCAGATA-3' and 
5'·CCTCACCTAGAACTGCCT·3') (28). The cycle conditions 
were identical to the conditions used for the mbr t(14:18) and 
resulted in a 7S0 bp IL·3 fragment detectable upon ethidium 
bromide staining. Samples were excluded from evaluation in this 
study when IL·3 amplification was not detected. 
In each experiment DNA from various dilutions (l0-LlO-6 ) 
of SU·DHL·6 cells in normal mononuclear blood cells was tested 
as a positive control. Routinely. the 10-2 dilution gave a band. 
visible after ethidium bromide staining; the 10-5 dilution was 
positive following hybridization. As negative controls. all reac· 
tion components without template DNA and all reaction com· 
ponents with DNA isolated from normal mononuclear donor 
cells were tested. Each DNA sample was analysed for breakpoint 
amplification in at least two independent experiments. Samples 
were considered to be positive when the amplified fragment 
hybridized with the mbr t(14:18) or mer t(14:18) BCL2 probes. 
In most samples amplification could be confirmed by hybridiza· 
tion with the JR probe. In the absence of specific amplification. 
a patient sample was evaluated as negative only when t(14:1S) 
specific amplification was successful in the 10-5 dilution of 
SU~DHL-6. If positive PCR data were not confirmed by other 
parameters (morphological or immunological analysis or clinical 
status) a second. independently isolated DNA sample was tested 
at least four·fold. 
Morphological Analysis 
Blood and bone marrow smears were prepared following routine 
methods and stained with May-Grilnwald-Giemsa for micro-
scopic examination. Leucocyte concentrates from peripheral 
blood samples were made. when the leucocyte count was below 
10 x 109/1. by using the pellet after centrifugation of the buffy 
coat. which results after sedimentation for 1 h at 37"C of 
anticoagulated blood. Smears. made from these pellets. were 
sereened for the presence of cells with abnormal morphology. 
Immunological Marker Analysis 
Mononuclear cells from blood and bone marrow were isolated 
by Ficoll-Isopaque density gradient centrifugation of anticoag-
ulated samples. Surface marker analysis was performed by 
indirect immunofLuoresence with the monoclonal antibodies 
CD19. CD20. CD3. CD4. CDS and HLA~DR (Becton Dickinson 
Sunnyvale. CA. USA). CD14 (Coulter aone, Hialeah. FL. 
UK). and CD15 (Dr W. Knapp. Vienna. Austria) (29) and 
FITC·conjugated goat anti·mouse immunoglobulin serum 
(Central Laboratory Blood Transfusion Service. Amsterdam. 
The Netherlands) as a second step. Direct immunofLuoresence 
was performed with FITC·conjugated goat anti·human IgM. 
IgD. IgG. IgA and lambda serum and TRITC-conjugated goat 
anti-human kappa and lambda serum (Nordic ImmunOlogical 
Laboratories Tliburg, The Netherlands). Double staining was 
performed with TRITC·conjugated kappa plus FITC-conjugated 
lambda or with the FITC-conjugated heavy chain expressed by 
the malignant B--cell (mostly IgM) plus TRITC-conjugated kappa 
or lambda. The preparations were read by microscope. Kappa 
and lambda ratios were determined by counting kappa or lambda 
positivity of 200 cells positive for the appropriate heavy chain. A 
B--cell population was considered to be monoclonal when more 
than 95% expressed kappa or lambda. With this procedure a 
monoclonal B--cell population of 0.1-1% in a mononuclear cell 
fraction after Ficoll~Isopaque centrifugation can be detected. 
RESULTS 
Incidence of t(14:18) in NHL 
Frozen lymph node biopsies were available and were 
investigated for the presence of an mbr or mer t(14;18) 
using both Southern blot and PCR analysis (Table 1) 
for 25 of the 79 NHL patients in this study. In 11 of 19 
biopsies from patients with follicular NHL, a t(14;18) 
was detected with both techniques, 10 having mbr 
t(14;18) and one mer t(14;18) positive cells. From the 
six patients with non-follicular types of NHL, one 
lymph node (diffuse cb/cc) showed mbr t(14;18) 
positive cells. Twelve paraffin embedded lymph node 
biopsies from follicular NHL patients were investigated 
using PCR. Nine biopsies were evaluable, four showing 
mbr t(14;18) positive cells and none mer t(14;18) 
Table 1. Analysis ot Frozen Lymph Node Biopsies and Paraffin 
Embedded L.ymphoma Tissue for the Presence Of a mbr or mer 
t(14;18) In Follicular NHL and In Other Types Of NHL (Three Diffuse 
cb/cc. Onc Diffuse cb. Ono Lymphoblastic and Onc Lymphocytic 
NHL.). Paraffin Embedded Material was Only Included When peR of 
the lL--3 Gene was Positive. 
Type of NHL No. 01 mb, m" Percentage 
Patlents positive 
Follicular CB/CC 28 '4 1 54 
Other types 6 1 0 17 
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pOSItIve cells. The overall incidence of t(14:18) in 
follicular NHL found in our patient group was 54%. 
Detection of Residual Lymphoma Cells by PCR 
Blood (138 samples), bone marrow (19 samples) or 
pleural effusion (two samples) from 74 NHL patients 
were investigated for the occurrence of mbr or mer 
t(14:18) positive cells using peR (Table 2). Nineteen 
of the 52 patients with follicular NHL showed on one 
or more occasions t(14:18) positive cells: 17 were 
positive for the mbr t(14;18) and two for the mer 
t(14;18). In six patients whose lymph node biopsies 
were positive for the mbr t(14;18). no mbr t(14;18) 
positive cells could be detected in blood or bone 
marrow (Table 2). From 22 patients with other types 
of NHL. six patients were positive for t(14;18) on one 
or more occasions, five for the mbr t(14;18) and one 
for the mer t(14~18) (Table 2). From these six patients 
five had diffuse centroblastic. centrocytic. or mixed 
NHL. Seventeen patients. negative for t(14;18) in the 
lymph node biopsy. did not show specific amplification 
products. indicating the specificity of the reaction and 
the absence of false positive reactions. 
An example of a peR analysis is presented in Figure 
1. DNA samples prepared from a blood specimen and 
from various dilutions of SU-DHL-6 cells (30) in 
normal cells were subjected to peR amplification and 
hybridization analysis. A fragment of approximately 
235 base pairs (bp) hybridizin? with both BeL2 and JH 
probes is found in up to 10- dilutions of SU-DHL-6 
cells. The reduced senSitivity of the JH probe is 
explained by the short JH homologous fragment (64 
bp) in the product (8). Analysis of two independently 
prepared DNA samples from a single blood sample 
from the patient showed amplification of an approxi-
mately 200 bp fragment with homology to both BeLZ 
andJH (Figure 1 lanes 1-4). The negative result in lane 
4 is explained by the low frequency of mbr t(14:18) 
positive cells in the blood sample. Owing to the 
reduced sensitivity of the JH probe and the presence 
of large (> 500 bp) non-specific amplification products, 
the BeLZ probe has been preferentially used for 
sereening purposes. 
Comparison of PCR With MOrphology and Immunological 
Marker Analysis 
From patients with t(14;18) positive NHL the peR data 
from blood or bone marrow were compared with the 
results of morphological examination and immuno-
logical marker analysis (Table 3). The samples were 
taken during treatment, at follow-up and. occasionally. 
at suspicion of relapse. In 15 of 22 samples, in which 
morphology revealed nO abnormal cells, t(14:18) pos-
itive cells were detected. In five samples both peR and 
morphology were positive. In 13 of 21 samples, in 
which immunological marker analysis was negative. 
peR analysis showed t(14;18) positive amplification 
(Table 3). Five samples, including two pleural effu-
sions, were both positive with peR and immunological 
marker analysis. The PCR data were not negative in 
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Table 2. PCR AnalySis of Blood. Bone Marrow, or Pleural Effusion 
for t(14;18) Positive Cells. Patients were Grouped According to 
t(14;18) Status of the (Primary) Lymph Node Biopsy. " Biopsy 
Material was not Available, Tumors Were Classified as Unknown. 
lymph Node No. 01 Patients No. of Palients 
Characteristics Tested PCR Posilive 
Follicular CB/CC (n '" 52) 
1(14;18) positive 12 6 
1(14;18) unknown 28 13 
1(14;18) negative 12 0 
Others {n '" 22:) 
1(14;18) Positive 0 0 
1(14;18) Unknown 17 6 
1(14:18) Negative 5 0 
Su·DHl·6 Patient 53 
-2 -3 -4 -5 2 3 4 
-1353 
-603 
-234 
-234 
Figure 1. PCR analysis of various dilutions from SU~oHl-6 cells 
(10-2_10-5) and from a blood sample of patient 53 (lanes 1-4). 
Lane 1, the result of the amplification from the first extracted DNA 
sample; lanes 2-4, from the second sample. Blots were hybridized 
to bOth the BCU and JH probe, washed In 3 x sse + 0.5% SOS at 
65->C. At the right, the size marker PhilX DNA digested with HaelU Is 
shown. 
Table 3. PCR AnalysiS of Blood, Bono Marrow, and Pleural Effu-
Sion From Patients With a t(14:18) Positive NHL Were Compared 
WIth the Staging Results (Number of Patients Between Brackets). 
M "" Morphological Examination, I = Immunological Marker Analy-
sis, CEO", Clinical Evidence of Disease, CCR"" Clinical Complete 
Remission. 
peR Results M-
" 
CEO CCR 
15 (13) 5 (4) 13 (11) 5 (4) 27 (16) 11 (5) 
7(5) 0 8(6) 0 6(3) 7(6) 
samples which were either morphologically or immuno-
logically positive. 
Comparison of PCR and Clinical Status 
In 30 patients with t(14;18) positive NHL. PCR data 
from blood or bone marrow samples were compared 
with the clinical status: 19 patients had CED by 
physical examination, imaging techniques. or had 
lymphoma cells in the blood or bone marrow by 
morphological or immunological analysis and 11 pati-
ents were in CCR. based on these examinations (Table 
3). Different patterns were seen. In 16 patients with 
CED, including the four patients with morphological 
and immunological positive samples, t(14;18) positive 
cells were detectable. In three patients with t(14;18) 
positive NHL. all follicular, who had CED only in the 
lymph nodes, no t(14:18) positive cells were detectable 
by PCR in the blood or bone marrow. These patients 
will be discussed in more detail. 
Patient A was a 47-year-old woman with follicular, 
predominantly centrocytic, lymphoma stage lUll. She 
showed a good partial remission after eight courses of 
CVP. The PCR analysis performed on blood samples 
taken after six and eight courses showed the presence 
of t(14:18) pOSitive cells. In the bone marrow taken 
after eight courses, no t(14;18) positive cells were 
found. Local radiotherapy was given on the upper 
abdomen. the only residual mass. Interferon-a main-
tenance treatment (3 x 106 IU three times a week) was 
given and further regression of the abdominal mass was 
noticed during the next few months. PCR analysis after 
5 and 8 months no longer revealed t(14;18) positive 
cells in the blood. 
Patient B was a 63-year-old women, in whom the 
diagnosis of NHL follicular cb/cc stage IVa with blood 
and bone marrow localization was made 10 years ago. 
She was treated several times with CVP courses and 
local irradiation. A search for t(14:18) positive cells in 
the blood was performed when she was receiving CVP 
treatment and pathological abdominal lymph nodes 
were the only clinical manifestation of the disease. No 
t(14;18) positive cells were detected by PCR. The 
blood and bone marrow remained morphologically and 
immunologically negative, whereas in a pleural effu-
sion, which was morphologically and immunologically 
positive for lymphoma cells, t(14:18) positive cells 
could be detected. 
Patient C was a 60-year-old woman with follicular 
NHL stage IlIu, who showed a CCR after eight CVP 
courses, but relapsed 10 months after treatment. A 
lymph node biopsy, taken at this relapse. was t(14:18) 
positive, CVP was restarted after progression on 
chlorambucil treatment. In a blood sample taken 
during CVP treatment. when small cervical and 
mediastinal lymph nodes were present, the PCR results 
were negative and remained negative 2 months after 
treatment and in second CCR. 
From the 11 patients in CCR. all of whom had 
follicular lymphoma, five patients showed t(14:18) 
positive cells in the circulation. The longest period of 
CCR after discontinuation of treatment until sampling 
of blood or bone marrow in these patients was 7,7,26, 
46. and 47 months. The longest period between two 
positive observations in the three patients who were 
tested more than once was 4, 7. and 14 months. In the 
other six patients, tested in CCR, no t(14:18) positive 
cells were detectable in the blood. They were tested 2, 
5,9,35.38, and 90 months after treatment. 
DISCUSSION 
In this study we used the sensitive PCR technique for 
the detection of t(14;18) positive lymphoma cells in 
blood and bone marrow from a large series of NHL 
patients. We show that it is a useful addition to the 
conventional staging investigations (10,26,31). The 
detection of a minor cell population by PCR is 
determined by the senSitivity of the technique, the 
sample error and the efficacy of the reaction. The 
sensitivity is limited by the maximum amount of DNA 
(up to 0.5 p.g. corresponding to the DNA content of 
100000 cells) that can be analysed per reaction. If the 
number of t(14;18) positive cells in the sample is 
around the detection limit, variability of the DNA 
sampling may affect the result of the PCR; sometimes 
a sample may give negative results (Figure 1, lane 4), 
whereas others, drawn from the same DNA prepara-
tion, show specific amplification (Figure 1, lanes 1-3). 
By enlarging the number of independent PCR experi-
ments, the sensitivity may be slightly increased. The 
efficacy of the reaction is determined by the quality of 
the DNA, in this study monitored by concomitant 
amplification of the IL-3 gene, and the reaction 
conditions, monitored by testing different dilutions of 
the t(14;18) positive cell line SU-DHL-6 in normal cells 
in the same experiment. Another limitation may be 
introduced by the heterogeneous distribution of lym-
phoma cells within a body compartment. Such a 
sampling error is less likely to occur in blood than in a 
bone marrow specimen. 
PCR analyses of lymph node biopsies showed ap-
proximately a 50% incidence of the t(14;18) in follicu-
lar NHL in our patient series. This frequency is 
relatively low compared with American studies (1,2) 
but in agreement with results of another European 
study (3). This discrepancy might be explained by 
variations in the definition for follicular growth pattern 
in NHL between pathologists or ethnological differ-
ences (3). The incidence of t(14;18) in diffuse types of 
NHL seems to be more frequent in diffuse lymphomas 
with centroblastic and/or centrocytic components (4). 
There is some evidence that these diffuse lymphomas 
originate from follicular lymphomas which underwent 
transformation to a higher malignancy grade (32-35). 
Comparison of the results obtained by PCR and by 
morphology or immunological marker analysis showed 
two general patterns. Firstly. PCR results were in 
concordance with the conventional analyses, both 
either positive or negative. In patients with t(14:18) 
negative lymph node biopsies no circulating t(14;18) 
positive cells were found in blood or bone marrow, 
indicating a lack of false positive results after t(14;18) 
amplification and the absence of circulating t(14;18) 
positive cells not related to malignant lymphoma (36). 
Secondly. positive PCR results were seen in otherwise 
negative samples. which indicates the greater sensitivity 
of the first (14,25.30). Comparison of the clinical status 
of the patient and PCR results showed concordant data 
in most, but discordance was seen in both directions. 
In five patients with follicular NHL in CCR we found 
t(14;18) positive cells in the blood up to 47 months after 
35 
discontinuation of treatment. This means that, if a 
leucocyte count of 6 x 109/l is assumed, and With a 
detection limit of one lymphoma cell in 100000 normal 
cells, more than 300 000 lymphoma cells are present in 
the circulation for several years without evidence of 
clinical relapse, On the other hand, three patients with 
t(14;18) positive follicular lymphoma and CED in the 
lymph nodes showed no t(14;18) positive cells in blood 
or bone marrow. Circulating t(14;18) positive cells 
were apparently absent or below the detection limit in 
these patients. This finding may be explained by either 
a low propensity of the lymphoma cells in some patients 
to spread into the circulation, or may be the result of 
treatment (31). Two patients (B and C) were tested 
during chemotherapy; one patient (A) was receiving 
interferon-a maintenance treatment. 
The clinical relevance of the presence of several 
thousand lymphoma cells in the blood of patients in 
CCR, especially in patients with t(14;18) positive 
follicular NHL, has to be studied further by a longer 
follow-up (none of the patients in this study in CCR 
with detectable lymphoma cells in the blood, as yet, 
has had a relapse). Also an accurate quantification 
procedure of the peR is required to establish progres-
sion of minimal disease in time. Various procedures 
have been described for semi-quantitative analysis 
(37,38), but serious problems have to be resolved to 
establish a reliable protocol. The clinical meaning of 
residual lymphoma cells in the blood with respect to 
remission duration may be different for the different 
types of NHL. 
As half of the patients with follicular NHL lack the 
t(14;18) marker, and the incidence is lower in other 
types of NHL, application of the PCR to t(14;18) 
breakpoint sequences is possible in a restricted number 
of the NHL patients. Amplification of the hypervari-
able DNA sequences of the VDJ segment of the 
rearranged immunoglobuline heavy chain gene, which 
provides a specific tumor marker, may allow a study of 
the clinical significance of residual disease in patients 
who lack this translocation, especially those with 
intermediate or high grade malignant NHL (39,40). 
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CHAPTER 3 
Translocation (14; 18)-positive cells are present in the 
circulation of the majority of patients with localized (stage I 
and II) follicular non-Hodgkin's Lymphoma. 
A.C. Lambrechts, P.E. Hupkes, L.C.J. Dorssers and M.B. van 't Veer. 
Blood 82: 2510·2516, 1993. 
Translocation (14;lS)-Positive Cells Are Present in the Circulation 
of the Majority of Patients With Localized (Stage I and II) 
Follicular Non-Hodgkin's Lymphoma 
By A.C. lambrechts. P.E. Hupkes, L.C.J. Dorssers, and M.B. van't Veer 
Stage I and II follicular non-Hodgkin'sJymphoma (NHL) is 
clinically defined as a localized disease. To study the possi-
bility that this disease is in fact disseminated, we used the 
sensitive polymerase chain reaction (peR) method using 
translocation (14; 18) as marker. Samples from 21 patients 
who were clinically diagnosed with stage I or II follicular 
NHL were analy2:ed for the presence of t(14;18)-positive 
cells using peR. We analyzed (1) the diagnostic lymph 
node biopsy and (2) the peripheral blood or bone marrow 
samples from these patients. Translocation (14:18) cells 
were detected in the diagnostic lymph node biopsies of' 2 
-.::;x>LUCULAR LYMPHOMA is the most common type 
~ of non-Hodgkin's lymphoma (NHL) in the United 
States and Europe. The majority of these patients present 
with disseminated disease (stage III and IV). After appro-
priate staging only 10% to 20% of the patients will be diag~ 
nosed as stage I or II. implying localized disease. )-3 These 
patients are usually treated with involved field radiotherapy 
(RT) alone. resulting in longstanding clinical complete re~ 
missions (CCR) and even cure. Relapse~free survival for pa~ 
tients with stage I or II follicular NHL is 83%, with a median 
follow~up of 6 years2.4~ a 14-ycar survival probability of72% 
for stage I and of 37% for stage 11 has been reporteci5 
In follicular NHL the reciprocal translocation between 
the longannsofchromosomes 14 and 18 [t(14~18)] is found 
in 55% to 70% of the patients in EurOpe.1.6.7 In American 
studies, an incidence of 70% to 95% is observed.S,? As a 
result of this translocation. the joining (JH) region of the Is 
hcavy chain (1gB) gene (14q21) is juxtaposed to the BCL-2 
gene (18q32).10-16 Two breakpoint clusters arc located 
within the non-coding part of the BCL-2 gene. the major 
breakpoint region (mbr) and the minor cluster region (mer). 
The mbr is involved in approximately 60% of the transloca-
tions and spans only 150 bases.12,14,17,18 The mer is found 
less frequently and involves a breakpoint region of 500 
bases. S,1?,20 In neither the peripheral blood of healthy donors 
nor in the peripheral blood and/or bone marrow from pa~ 
tients with t(l4;18)-negative NHL. could t(l4;18)-positive 
cells be detecteci 3 The t( 14; 18) therefore provides a unique 
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patients. In 9 of these patients, t(14;18)-positive cells 
were detected in peripheral blood and/or bone marrow 
samples at diagnosis and/or after therapy. Thus, in 75% of 
the follicular NHL patients carrying the t(14;18) as a 
marker for lymphoma cells, t(14;181-posrtive cells were 
detected in peripheral blood and bone marrow at diagnosis 
and after therapy. Our results show that t(14;18)-positive 
cells can be detected in the circulation of patients with 
stage I and 11 follicular NHL. indicating that. although diag-
nosed as localized, the disease is disseminated. 
© 1993 by The American Society of Hemlltology. 
marker for the lymphoma cells and a suitable target for the 
polymerase chain reaction (PCR). 
We present a retrospective study in which the presence of 
t(14;18)-positive cells is demonstrated in peripheral blood 
and/or bone marrow from stage I or II follicular NHL pa~ 
tients. Our results show that in the majority of these patients 
t(14;18)-positive cells are present in the circulation both at 
diagnosis and after therapy. These results indicate that stage 
I and II follicular NHL is often not a localized but a dissemi~ 
nated disease. 
MATERIALS AND METHODS 
Patienls. Twenty-one patients initially included in this study 
were diagnosed with follicular centroblastic centrocyt:ic NHL ac-
cording to the Kiel classification?1 The slides of the lymph node 
biopsies were reviewed by a panel of pathologists. Staging of these 
patients was performed according to the Ann Arbor classification. z: 
The Staging procedures included physical exam.ination. CT scan of 
thorax and abdomen. morphologic examination. and immunologic 
marker analysis of peripheral blood and bone marrow aspir:ltes.' 
These procedures were repeated after ther.lPY and at regular inter~ 
vals during follow-up. For patients in CCR. neither morphologic 
examination nor immunologic marker analysis showed the pres-
ence of lymphoma cells in the peripheral blood or bone marrow. 
Most patients were treated with surgical excision or were involved 
in field radiother.lPY. some in combination with chlorambucil. All 
patients had given informed consent to donate peripheral blood 
and bone marrow. 
DNA extraction ami analysis. High molecular weight DNA was 
prepared from frozen lymph node biopsies and fresh peripheral 
blood and/or bone marrow cells according to previous described 
methods.3 Frozen lymph node biopsies were avail:lble from nine 
patients and were subjected to Southern blot and PCR analysis.3 
For hybridization the following probes were used: aJH probe. spe-
cific for the joining regions (JH3--JH6) of the IGH gene~ a BCL--2 
probe specific for the mbr t(14;18). gift from Y. Tsujimoto;11 and 
the pfL..2 probe specific for the mer t(14;18). gift from M.L 
Geary. I" Paraffin embedded lymph node biopsies wereanalyzed by 
PCR in 12 patients. DNA from pamfEin embedded lymphoma 
biopsies w.lS isolated as follows: Two 6 ,11m sections were deparaffin~ 
ated by xylene (twice for 5 minutes). washed with 96% and 70% 
ethanol. and dried. The sections were incubated for 12 to 18 hours 
at 37"C in 200 Jl.L tissue preparation mixture (0.75 x PCR buffer 
[Promega. Coopemtion. Lciden. The Netherlands). 0.5% Tween~20. 
and200 Jl.'l1mL proteinase K). Thesamples were heated to 95"Cfor 
8 minutes. extracted with phenol/chloroform. and precipit:lted 
withsodiumacetateand ethanol. The DNA wasresuspended in 100 
~L 10 mmol/L Tris.HCI (pH 7.4): I to 10 ~L was used for the in 
vitro amplification by PCR. 
In vilro DNA amplification by peR. Two different PCR strate-
gies were used to detect mbr t(14:IS)-positive cells in peripheral 
blood and bone marrow from suge I and II NHL patients. For 
one-step PCR, 1 ~L of DNA in a reaction volume of 50 ~L was 
subjected to 30 cycles of PCR amplification using an automated 
Perkin-Elmer/Cetus DNA Thennal Cycler (Gouda. The Nether-
lands). Taq DNA polymer.lSC (Promcga: 0.40 U), and the recom-
mended buffer conditions. Thirty-five to 40 pmol of JH 16 and 
BCLI S in a volume of 50 ILL was used (Table I). Primers were 
synthesized by Pharmacia Nederland BV (Woerden. the Nether-
lands). The optimal cycle conditions were 94°C for 4 minutes: sub-
sequently 30 cycles of 1 minute at 94°C. 2 minutes at 58°C. 2 
minutes at noc. followed by a final extcnsion of 7 minutes at 
noel To generate ethidium bromide visible products 1/50 of the 
amplified product was reamplified in 20 cycles using 35 to 40 pmol 
of "nested" JH20 and BCLIS in a reaction volume of 50 ILL. The 
nested JH20/BCU8 amplified products were 13 bp shorter than 
the PCR product generated after amplification with JHI6 and 
BCL18.1o (Table 2). For two-step PCR, 50 ILL PCR reaction mix_ 
ture included 0.5 U ofTaq DNA polymerase, 0.35 to 0.40 pmol of 
the primers JHI6 and BCUO, and 35 to 40 pmol of the primers 
JH 14 and BCLI8 (Table I). The cycle profile wasdemlturing for 5 
minutes at 94°C in the first cycle and for 45 seconds in the subse-
quent 39 cycles. In the first 10 cycles. annealing was performed :It 
65°C for 2 minutes.. permitting only primers JH16 and BCUO 
(present in a limiting amount of 0.35 to 0.40 pmol) to hybridize to 
the urget DNA. In the next 30 cycles annealing was at 54°C for 2 
minutes allowing primersJH 14 and BCLI8 to hybridize. Extension 
of the annealed primers was at 72°C for 2 minutes. followed by a 
final extension at noe for 7 minutes. For the detection of mer 
t(l4;18}-positive cells primers JHI6 and BCLMCI2 were used 
under the same conditions as described for the detection of mbr 
t( 14: I 8}-positive cells in the one step PCR (Table 1 ).,q One fifth of 
the amplified DNA was analyzed on a 1.2% agarose gcl followed by 
Southern blot analysis with the BCL-2 or pFL-2 probe. J 
Asa control to DNA quality. a 750-bp fragment of the interleu-
kin-3 (IL-3) gene was amplified in 25 cycles. using primers IL-3/2 
and lL-3/9 e (Table I). Provided that this IL-3 fragment was visible 
on ethidium bromide sUining. results of the t(l4~18) PCR were 
evaluated. For the mbr t( 14:18) amplification. DNA extracted from 
SU-DHL-6 cells diluted in normal mononuclear blood cells (up to 
1 O-~ dilution) was used as a positive control. With the one-step PCR 
the 1O-~ dilution of SU-DHL-6 resulted in a ethidium bromide 
band visible on gel. and the 10-' dilution ofSU-DHL-6 was positive 
following hybridization with the BCL-2 probe. With the two step 
PCR the 10--1 dilution of SU-DHL-6 cells was positive after ethid-
ium bromide staining. and the presence of mbr t(14;18}-positive 
Table 1. Code and Sequence of Oligonucleotides 
Used for PCR Analysis 
Codo of Primer 
JH14 
JH16 
JH20 
BCllS 
BCL20 
BCLMC12 
Il-3j2 
Il-3j9 
Il-3/11 
S' - 3' Soquenco of PrlmQf 
AGGAGACGGTGACC 
TGAGGAGACGGTGACC 
ACCAGGGTTCCTTGGCCCCA 
GGTGGTTTGACCTTTAGA 
TAAAAATCCAGATGGCAAAT 
TTGATGGCTTTGCTGAGA 
GAGGTTCCATGTCAGATA 
CCTCACCTAGAACTGCCT 
CATCGATCATGTTAGAGC 
cells in the 10-5 dilution was confirmed by hybridization. For the 
mert( 14: IS) PCR. DNA from an mcr t( 14: 18}-positive lymph node 
biopsY was diluted in DNA from normal mononuclear blood cclIs. 
Up to the JO-~ dilution hybridization was seen with the pFL-2 
probe. The detection limit of both mbr- and mcr-t(14;IS)-positive 
cells was estimated to be approximately I t( 14:IS)-positive cell out 
of I 00.000 normal cells. Each DNA sample was analyzed for break-
point amplification in at lem.1. two independent experiments. From 
the isolated DNA samples, at least two separate dilutions were 
made from a stock DNA sample and tested with PCR. Samples 
were considered to be positive when an amplified fragment hybrid-
ized with the BCL-2 or pFL-2 probe. Only those experiments were 
evaluated in which the positive control was successfully amplified 
up to a 10-) dilution. 
The quality control for DNA isolated from paraffin embedded 
tissue is slightly different. We used the same cycle profile for the 
SU-DHL-6 dilutions to esublish the sensitivity of each individual 
experiment. DNA rrom paraffin embedded tissue was amplified in 
40 cycles using the primers IL-3/2 and IL-3/11. resulting in a 300-
bp fragment visible on ethidium bromide suining. To amplify this 
IL-3 fragment. severa.! DNA dilutions of paraffin embedded tissue 
were tested. In most samples. no 750-bp IL-3 fragment could be 
amplified with the primers IL-3j2 and IL-3/9. Ift(l4;18)-specific 
PCR products could not be detected by hybridization in three inde-
pendent amplification experiments. than the diagnostic lymph 
node biopsy was considered to be negative for t(14:18). 
Sequence anal.vsis. Sequence analysis by the dideoxy chain ter-
mination method was performed on PCR product of patient ME. 
DNA was amplified with the BCL20 andJH 16 primers. An approxi-
mately 1.050-bpfragment wasdetecte<l on cthidium bromidestaln-
ing. This fragment was isolated out of the gel. reamplificd using 
BCL18 and JH 16, and cloned into the Sma I site ofPTZJSR. The 
sequence was analyzed using the Pharmacia T7 sequence kit. 
RESULTS 
Definition of the patients USed in li1issludy. Twcnty-one 
stage I and stage II follicular NHL patients (Table 3) were 
studied for the presence of t( 14: lS}-positive cells in (I) the 
diagnostic lymph node biopsy and (2) peripheral blood and 
bone marrow at diagnosis and during follow-up after ther-
apy. Immunocytochemistry confinned monoclonality of 
the diagnostic lymph node biopsy in 13 patients using K and 
A light chain antibodies (Table 3). The remaining eight 
biopsies. all paraffin-embedded. were studied using an anti-
body directed against BCL-2. Z4 All these biopsies were posi-
tive for BCL-2 protein expression in the follicles (Table 3). 
In a reactive lymph node biopsy the follicle centers were 
negative for BCL-2 protein expression in contrast to the 
mantcl zone. where BCL·2 protein expression was detected. 
The t{ 14; 18) was detected by PCR using two specific primer 
sets. defining either the mbr or the mer breakpoint of 
t(14:18) (Table I). Using the mbr specifie primer set we 
detected an amplified product of 1 00 to 300 bp in the major-
ity of the t(J4:IS}-positive patients (Fig I). Translocation 
(14: 1 S)-positive cells were identified in 13 patients. either in 
the diagnostic lymph node biopsy or in peripheral blood 
and bone marrow samples. In 12 of those patients. t(14:18) 
was demonstrated in the diagnostic lymph node biopsies on 
frozen tissue (n "" 5) using both Southcrn analysis and PCR 
analysis or on paraffin-embedded tissue (n "" 7) using PCR 
only (Table 3). 
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SA 
SD 
SM 
DH 
DL 
DO 
" 
ME 
00 
sw 
TE 
TH 
W1 
Table 2. Clinical Characteristics and PCR Results From Patients With t(14;18J~Positive Stage I and II 
Follicular NHl at Diagnosis and During Follow"up 
Bro~kpolnt/Sizo 
MBRj200 
MBR/180 
MBR/230 
MBR/190 
MBR/280 
MBR/120 
MBR/180 
MBR/1000 
MeR/600 
MBR{300 
MBR/160 
MBR/200 
MBR/220 
F~low-up 
(in months) 
D 
D 
D 
D 
+3 
o 
o 
o 
D 
+156 
+168 
D 
D 
+4 
D 
D 
o 
+4 
+7 
+13 
+17 
+20 
+23 
D 
D 
o 
+32 
+44 
+51 
+55 ~ 0' 
+55 ~ 0' 
+6' 
D 
D 
+4 
D 
+56 - 0' 
+4' 
+6' 
+W 
+16' 
D 
+24 
o 
+96 
+100 = 0' 
+7' 
+W 
+19' 
D 
D 
D 
+7 
+1D 
+1D 
LN 
PS 
LN 
SM 
PB 
LN 
PB 
SM 
LN 
PS 
PS 
LN 
PS 
PS 
LN 
PS 
SM 
PB 
PS 
PS 
PS 
PS 
PS 
LN 
SM 
LN 
PB 
PB 
PS 
PB 
SM 
PS 
LN 
PS 
PS 
SM 
PS 
PS 
PS 
LN 
LN 
PB 
PS 
LN 
PS 
PS 
PS 
LN 
PS 
SM 
PS 
PB 
SM 
'm 
+ 
+ 
NT 
+ 
+ 
NT 
NT 
+ 
NT 
+ 
NT 
NT 
NT 
NT 
+ 
+ 
NT 
NT 
NT 
NT 
+ 
NT 
+ 
NT 
NT 
NT 
NT 
+ 
NT 
+ 
NT 
NT 
NT 
+ 
NT 
MO 
+ 
+ 
NT 
+ 
+ 
+ 
NT 
+ 
NT 
NT 
NT 
+ 
NT 
+ 
NT 
NT 
NT 
NT 
+ 
NT 
NT 
NT 
+ 
NT 
+ 
NT 
NT 
NT 
+ 
NT 
eo, 
t114;18) 
Positive 
Positive 
+ 
+ 
Positive 
+ 
Positive 
Positive 
+ 
Positive 
+ 
+ 
+ 
+ 
+ 
+ 
Positivo 
+ 
+++ 
+++ 
+++ 
+++ 
+++ 
+++ 
Positive 
+ 
++ 
++ 
++ 
++ 
Positive 
Positive 
+ 
Positive 
+ 
+ 
Positive 
+ 
+ 
+ 
Oinleal 
$Ultus 
CCR 
CCR 
CCR 
CCR 
CCR 
CCR 
CCR 
CCR 
CCR 
CCR 
CCR 
CCR 
CCR 
Relapse 
NC 
CCR 
Re[apse 
NC 
NC 
NC 
NC 
1 
CCR 
CCR 
Rolapse 
CCR 
CCR 
CCR 
CCR 
CCR 
CCR 
Th«apy 
RT 
Surgery 
RT + chem 
RT 
RT 
RT 
Surgery 
RT 
RT 
RT 
No 
Surgery 
RT 
RT + cham 
Surgery 
RT 
Translocotion (14;18) results aro presented as follows: diagnostic lymph node (positive); ethidium bromido visiblo bands (+++); no ethidium 
bromide visible band but strong signal aftor hybridization (++); signal at throshold of detection after hybridization (+). 
Abbreviations: " months after local rolapse; BM, bone marrow; eCR, clinical complete remission; chern, chomotherapy; 1m, immunologic marker 
analysis; LN, lymph node; Mo, morphologic examination; NC, no charge; NT, not tested; Ps, peripheral blood; RT, radiotherapy. 
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Table 3. Details of Follicular Centroblastic Centrocytic NHL Patients and Their Lymph Node Biopsies 
Pmlon! Ago IV') Stago loCIIl'>:l.IllOn 
BA 77 M Axillo left 
BD 61 SupraclOvicular left 
BM 75 Cutaneous forehead 
DB SS Orbita left and right 
DH 65 Supraclovicular left 
DL 45 Supraclilvicular left 
DO 54 Supraclavicutor left 
IL 45 Parotis right 
<H 78 Supraclavicular right 
<0 63 Subrmlndibular right 
<v 41 Subm(lndibulor left 
LB 25 Axilla right 
Froron or 
Paraffin 
P 
F 
F 
P 
P 
P 
P 
P 
tI14;18) 
+ 
+ 
+ 
, 
+ 
+ 
+ 
+ 
Immunology 
aCL·2 Immunology 
+ NE 
+ NE 
+ 
+ N' 
+ N' 
+ X 
LW 71 
M 
M 
M 
M 
M 
M 
M 
M 
F 
M Orbita and cervi~llef1: P X 
M' 5B Groin left 
PO 62 Axillo loft 
ao 60 Suproclovicular left 
SW 66 Axillo right 
TE 51 Parotis right 
P 
P 
F 
P 
P 
+ 
+ 
+ 
+ NE 
+ N' 
+ N' 
TH 52 
M 
F 
F 
M 
Submonolbulilr and axHia left X 
VR 58 Thorax wall 
WI 58 Cervi~1 right ::md loft P + + NE 
Characteristics of patients and the 10000hzation and stoge of the disease oro designated. From the diognostic lymph node either frozen (F) or pal1lffin 
(P) embedded tissue wos lIvailoble and lInolyzcd for t(14;18). Detection of t(14;18) by Southern onalysis on frozon tissue or by PCR on powffin 
embedded tissue (+); absence of t(1 4;1 8) (-); detection oft(14;18) on frozen tissue using PCR, which could nOt be confirmed by Southem tlnolysis (a). 
Immunocytochemistry using the ontibodies directed ogains! the ~ and A Iglight chains was performed on frozen tissue to confirm monoClonality (~or A) 
at diagnosis. On paraffin·ombo<lded tissue monoclonality could not be evolu.:ltod using ~ and A ontibodies (NE). BCL-2 protein expression wos detected 
in all the poroffin embedded tissues studied using on antibody BCL-2 100", (+J. 
In 1 patient (ME), t( 14;18)-posltive cells were detected in 
peripheral blood and bone marrow during follow-up on dif-
ferent occasions. but could not be confirmed in the paraffin-
embedded. diagnostic lymph node biopsy. The reason for 
this discrepancy could be that the amplification product was 
large (approximately 1.000 bp), in comparison to the usual 
Fig 1. t(14;18)-positive cells from lymph node 
biopsy and circulation yield identical PCR frag-
ments. t(14;18)-spocific PCR products were gen. 
erated after reamplification of JH16jBCL 18 prod-
ucts using tho nested JH20 and BCL18 primers. 
Samples from the diagoostic lymph node biopsy 
(LN) and peripheral blood (PS) were compared. Tho 
results from 5 patien"t$ are shown. In addition the 
10-~ dilution of SU-OHL-6 (SU) is shown. At the 
left, the si%e marker PhlX X Haem and at the right 
a 100-bp SilO ladder is shown. The estimated sile 
of the PCR products is 160. 180, 200, 260, and 
280 bp, respectively; tho sile of the SU-DHL-6 
fragment is 222 bp." 
603 
310 
281 
271 
234 
194 
Ph'" 
Haelll 
1 00- to 300-bp fragments. DNA isolated from paraffin-em-
bedded tissue is often of relatively poor qua.lity and does not 
allow amplification of large fragments. The fact that we 
could amplify the control 300-bp IL-3 fragment but not the 
750·bp IL-3 fragment indeed showed that the paraffin-de· 
rived DNA from this patient was in poor condition. Se-
BO BD TH TH WI WI DL DL SW SW SU 100bp 
LN PB LN PB LN PB LN PB LN PB 
600 
SOD 
400 
300 
ZOO 
100 
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quence analysis of the 1.000-bp PCR product showed that 
the fragment consisted of951 bp homologous to the BCL~2 
gene plus 52 bp homologous to the JH6 sequence. The 
breakpoint on chromosome 18 is exceptional in that it is 
800 bp downstream of the robr. So far. only breakpoints 
upstream of the mbr are described. 16.25 The PCR product 
that we detected in peripheral blood and bone roarrow from 
patient ME is thus derived from the junction between the 
BCL-2 and JH gene. Therefore. we include this patient in 
our analysis of the 13 patients with t(14;18)-positive NHL. 
Six of the 21 patients were negative for t(14;18) in the diag~ 
nostic lymph node biopsy. and in peripheral blood and 
bone marrow at diagnosis and/or after therapy. Two of the 
21 patients (DB and KO) were excluded from evaluation in 
this study for different reasons. In the frozen lymph node 
biopsy from patient DB. t(14:18)-positive cells were identi~ 
tied only by PCR. Southern analysis showed one rearranged 
Ig heavy chain gene and no translocated BCL.2 gene. It was 
concluded that these t( 14;lS)-positive cells did not represent 
the monoclonal B-ccll population. One peripheral blood 
sample from patient KO contained low numbers of 
t( 14: IS)-positive cells 11 years after diagnosis. The presence 
of this translocation could not be continued in the parnffin~ 
embedded diagnostic lymph node biopsy, probably due to 
inferior quality of the DNA isolated. 
In conclusion, samples from 13 of21 patients that were 
analyzed contained t(14:1S)-positive cells. Clinical charac~ 
teristics and PCR results from patients with t( 14; lS)-posi~ 
tive NHL arc summarized in Table 2 and will be discussed 
in more detail in the next sections. 
Presence oJt( 14:1 8)~positive cells in peripheral blood and/ 
or bone marrow at diagnosis. From the group of 12 pa~ 
tients with t(I4;lS)-positive cells in the diagnostic lymph 
node biopsy, we collected peripheral blood and/or bone 
marrow samples at diagnosis from S of them. Of six patients 
from whom we had peripheral blood, 3 were positive for 
t{14;lS) cells (DO, QO and WI [Table 2]). Of 5 patients 
from whom we had bone marrow, all 5 were positive for 
t(14:18) cclls (BD. BM. DO, IL. and WI). In patients DO 
and WI. both peripheral blood and bone marrow contained 
t( 14; 18)-positive cells. Thus. in 6 of the S patients analyzed. 
t(14:1S)-positive cells were detected in the circulation at 
diagnosis. 
Presence oJt(1 4:1 8)~positive cells in peripheral blood and/ 
or bone marrow after therapy. From the group of 13 pa~ 
tients with t(14;lS)-positive NHL. we collected peripheral 
blood and/or bone marrow after therapy from 10 of them. 
Of 10 patients from whom we had peripheral blood. 7 were 
positive for t(14;I8) cells (BD. DL. DO. ME. SW. TH. and 
WI [fable21). Of3 patients (ME, SW. and WI) from whom 
we bad bone marrow. 2 were positive fort(14;18) cells (ME 
and SW). Both peripheral blood and bone marrow from 
these 2 patients contained t(l4:1S)-positive cells. In the 
bone marrow from patient WI, no t(l4;18)-positive cells 
were detected, but the peripheral blood taken at the same 
time contained t(14:18)-positive cells. Thus. in 7 of the 10 
patients analyzed, t(l4;18)-positive cells were detected in 
the circulation after therapy. 
Translocation (I4:18)-positive cells from lymph node 
44 
biopsy and circulation yield identical PCR products. To 
exclude the possibility that the t(14;lS)-positive cells from 
the diagnostic lymph node biopsy and from the circulation 
contained a different t(14;lS) breakpoint. we compared 
their PCR products. In all 9 patients who had t( 14:IS)-posi~ 
tive cells in the diagnostic lymph node biopsy and in the 
circulation. we found amplified DNA fragments of identical 
size. This is shown for 5 patients in Fig 1 and for 1 addi~ 
tional patient in Fig 2. The difference in size (100 to 300 bp) 
of the nested PCR products among 5 different patients is 
also ill.ustrated in Fig 1. 
Clinical course in patients withJollicu1ar NHL. The to-
tal number of patients with t(14;IS)-positive cells in the cir-
culation. either at diagnosis or after therapy is 10 of the 13 
patients with t(l4;IS)-positive NHL (Table 2). We evalu~ 
ated the clinical course of these 10 patients. Three of these -
patients relapsed 55, 60. and 100 months after initial ther-
apy; the mean duration of the CCR being 72 months. Five 
oftbese patients are in ongoing CCR. with a mean follow-up 
of 9 months (range. 3 to 23 months). For the remaining 2 
patients. no follow-up samples were available. Of the 3 pa-
tients with t( 14:18)-positive NHL but without t( 14:1S)-posi-
tive cells in the circulation. 2 patients were in CCR for 24 
and 172 months, respectively. 
Three of the 6 patients with t(14:18)-negative NHL were 
in CCR at the moment of evaluation. with a fol1ow~up of3. 
15. and 23 months. respectively. Oftbe other 3 patients. no 
follow~up samples were available. One patient (DO) with a 
relatively long follow~up and circulating lymphoma cells 
will be discussed in more detail to illustrate the course oftbe 
disease. mbr t( 14: 18)-positive eells could be detected in the 
diagnostic lymph node biopsy and in the peripheral blood 
and bone marrow taken at diagnosis (Fig 2). While the pa-
tient was in CCR. faint t(14;lS)-specific bands hybridizing 
with BCL-2 were detected in the peripheral blood 4. 7. 17. 
and 23 months after local radiotherapy. This indicates a low 
amount of circulating t(14:1S)-positive cells. In the periph-
eral blood samples taken after 13 and 20 months, no mbr 
t(14;lS)-positive cells could be detected (Table 2). In Fig 2. 
the results of one experiment are shown. The peripheral 
o o 4 7 13 17 20 23 
• ---
.. 
Fig 2. The course of the follicular NHL in 1 patient as indicated 
byt(14:18)-specific peR frngments. t(14:18) PCR frngments were 
generated from the diagnostic LN. PB. and bone marrow (BM) from 
patient DO at diagnosis and at various time points (indicated in 
months) after completion of therapy. The 120-bp t{14;18)·specific 
frngments were visualized by hybridization with the BCL·2 probe. 
For LN 1{50 oftheamplificd product and for PB and BM 1/Softhe 
amplified product was loaded. 
blood samples taken after 7. 13. and 20 months contained 
no detectable t(14:1S)-positive cells. However. in two addi~ 
tional experiments, we could detect t(14:IS)~positive cells in 
peripheral blood taken after 7 months. These results indi~ 
cate that the amount of circulating t(14:1S)-positive cells is 
apparently at the threshold of the detection. 
DISCUSSION 
In this report we described the presence oft(l4:1S)-posi~ 
tive cells in the circulation of patients with localized (stage I 
and II) t(l4:1S)-positive follicular NHL. Translocation 
(14:1S)-positive cells in the diagnostic lymph node biopsy 
were detected with an overall incidence oft( 14:1S) in 63% of 
the patients (12 of 19). In the group of patients with 
t(14: IS}-positive NHL. we detected t( 14: IS}-positive cells in 
the circulation at diagnosis and after therapy. with an inci~ 
dence of about 77%. The fragment sizes of the amplified 
products from peripheral blood and/or bone marrow sam~ 
pies were identical to the fragment sizes of the t( 14:1S)-spe-
cific products in the corresponding lymph node biopsies 
(Figs 1 and 2). The circulating t(14:IS)-positive cells are 
therefore most probably lymphoma cells. identical to the 
t(14:IS}-positive cells in the diagnostic lymph node biopsy. 
We conclude from these results that stage I and II 
t( 14: lS}-positive follicular NHL. diagnosed as localized dis-
ease according to conventional staging techniques. is al~ 
ready disseminated at diagnosis. Furthermore. therapy does 
not eradicate the circulating t{14;lS}-positive cells. 
The sensitivity of the PCR method for detecting 
t{14:1S)-positive cells implies that about 300.000 t{14:1S)-
positive cells are present in the circulation of patients with a 
normal leukocyte count for long periods of time. J..Z6 This 
evokes the question about what the presence of t( 14: IS}-po,Y 
itive cells in the circulation of these stage I and II follicular 
NHL patients means with respect to the risk of relapse. 
These patients usually have a favorable prognosis. In this 
study 3 (ME. SW, and TH) of the 10 patients with 
t(14:1S)-positive cells in the circulation had a clinical re-. 
lapse. In 2 of them (ME and SW). a high frequency ofcircu~ 
lating t(l4:1S)-positive cells was detected. In the other pa-
tient (TH). the frequency of circulating t(l4:1S)-positive 
cells remained near the detection limit ofPCR analysis. The 
frequency of circulating t( 14:1S)-positive cells in all patients 
in continuing CCR was near the threshold of detection by 
PCR (Fig 2). The small group of patients analyzed. does not 
allow us to make a connection between the presence of 
t(14:1S)-positive cells in circulation and the prognoses of 
these patients. A longer follow~up period and refinement of 
the quantification procedure of the PCR arc necessary to 
:lddress this question. 
The biologic relevance oft( 14: lS)-positive cells in the cir-
culation of patients with follicular lymphoma is unclear. 
Two mechanisms could be responsible for this phenome~ 
non. The high expression of the BCL-2 oncogenc, present in 
t( 14: IS)-positive cells may prevent a slowly expanding clone 
from apoptosis.~7 lfse, it is expected that every patient with 
t( 14: lS}-positive cells will eventually relapse. The other pos-
sibility is that the t( 14:18) marks only a premalignant status. 
In that case. an additional, so far unknown event. may 
transform one of these cells to malignancy resulting in a 
local manifestation of the disease. Local therapy may eradi-
cate the malignant clone in stage I and II NHL and reduce 
the disease to a premalignant status. In this case, p:ltients 
may be cured not withstanding the presence oft( 14: IS)-posi-
tive cells. In favor of this second possibility is the finding 
that low numbers oft(14:1S)-positive cells have been de-. 
tected by PCR in benign follicular hyperplasia. 28 Similarly. 
the low numbers of t(l4:18)-positive cells detected in the 
frozen lymph node biopsy from patient DB most probably 
represent preIllillignant t(l4:1S)-carrying cells. 
Our study provides strong evidence that stage I and II 
follicular NHL are usually disseminated diseases. However. 
at present we do not know the significance of the presence of 
t( 14; lS}-positive cells in circulation in stage I and II follicu-
lar NHL patients with regard to the risk of clinical relapse. 
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CHAPTER 4 
Clinical significance of t(14; 18)-positive cells in the 
circulation of patients with stage III or IV follicular non-
Hodgkin's lymphoma during first remission. 
A.C. Lambrechts, P.E. Hupkes, L.C.J. Dorssers and M.B. van 't Veer. 
Journal of Clinical Oncology in press. 
SUMMARY 
Purpose: To evaluate polymerase chain reaction (peR) analysis as a method for the 
detection of circulating lymphoma cells in patients with stage III and IV t(14;18)-
positive follicular non-Hodgkin's lymphoma (NHL) in first remission in a longitudinal 
prospective study. 
Patients and Methods: Peripheral blood or bone marrow from eight patients with stage 
111 and IV t(14;18)-positive NHL was studied using PCR to detect the presence of 
t(14;18)-positive cells in the circulation at different time points during first remission. 
Results: In four of six patients with no clinical evidence of disease (NeED), t(14;18)-
positive cells were detectable in the circulation. In one of two patients with clinical 
evidence of disease (CEO), no t(14;18)-positive cells were found at the four different 
occasions tested during first remission. First-remission duration ranged from 17 to 81 + 
months. The duration from the first peR determination in remission until first relapse or 
the end of the observation period ranged from 10 to 37+ months. 
Conclusion: In patients with stage III and IV t(14;18)-positive follicular NHL treated 
with conventional remission induction therapy, the presence or absence of t(14;18)-
positive cells in the circulation shows no obvious correlation with the clinical remission 
status and the remission duration. 
INTRODUCTION 
Follicular non-Hodgkin's lymphoma (NHL) accounts for approximately 45% of all NHLs 
(1,2). In 60% to 85% of patients, it is characterized by a specific chromosomal 
translocation between chromosomes 14q32 and 18q21 [t(14;18)] (3-7l- As a result of 
this translocation, the joining (JH) region of the immunoglobulin heavy chain (lgH) gene 
(14q32) is juxtaposed to the BCL-2 gene (18q21) and a hybrid BCL2/JH sequence, 
unique for the NHL cells, is created (8-12). Two breakpoint clusters are located within 
the 3' non-COding part of the BCL-2 gene, the major breakpoint region (mbr) and the 
minor cluster region (mcr)(13). The mbr is involved in 60% to 70% of the 
translocations and spans only 150 bases (10,14-16). A mer breakpoint is found in 20% 
to 30% of the translocations and involves a breakpoint region of 500 bases (6,13,17). 
Thus, the t( 14; 18) provides a unique marker for the NHL cells and a suitable target for 
the sensitive in vitro DNA amplification technique, the polymerase chain reaction 
(PCR)(18). 
Follicular NHL is classified as a low-grade malignant NHL and has a relatively 
indolent course (19). The majority of the patients (range, 80% to 90%) present with 
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disseminated disease that is restricted to lymph nodes (stage III) or also includes 
peripheral blood, bone marrow and organ localization (stage IV)(20). These patients are 
usually treated with chemotherapy. Most patients respond to therapy and about half of 
the patients achieve a clinical complete remission (21,22). The median first-remission 
duration for stage III and IV follicular NHL patients is reported in different studies to 
range from 18 to 28 months (21). In addition to conventional techniques such as 
imaging of lymph nodes and detection of NHL cells in the circulation (peripheral blood 
and bone marrow) by morphological examination and immunological marker analysis, 
peR on the breakpoint regions of t(14;18) is used for the detection of minimal disease 
(3,23,24). 
We report here the results of peR analysis on peripheral blood and/or bone 
marrow cells in a longitudinal study, to evaluate this technique as a method for 
detection of minimal residual disease in patients with stage III and IV t(14;18)-positive 
follicular NHL in first remission. 
MATERIALS AND METHODS 
Patients: All patients in this study were diagnosed with stage III and IV (20) follicular 
centroblastic centrocytic NHL (25). The slides of the lymph node biopsies were reviewed by a 
panel of pathologists. Only those patients were included in whom the lymph node biopsy at 
diagnosis contained t(14; 181-positive NHL cells. The staging procedures included physical 
examination, computed tomographic scan of thorax and abdomen, morphological examination, 
and immunological marker analysis of peripheral blood and bone marrow (3). These procedures 
were repeated after therapy and at regular intervals during the follow-up period. All patients 
were initially treated with 8 courses of combination chemotherapy (cyclophosphamide, 
vincristine and prednisone (CVP)) every four weeks (according to EORTC trial 20586). This 
initial chemotherapy was aimed at the highest reduction of disease. After chemotherapy, 
radiotherapy was administered to residual enlarged lymph node masses if present. Patients were 
then randomized for treatment with interferon-a or no further treatment. All patients had given 
informed consent to donate peripheral blood and bone marrow. 
DNA extraction and analysis: DNA extraction, Southern blotting, in vitro DNA 
amplification by PCR, and analysis of PCR products was performed as described previously 
(3,23). A frozen lymph node biopsy was available from one patient, and DNA from this biopsy 
was subjected to Southern blotting and PCR analysis (3). Paraffin-embedded lymph node 
biopsies were available from seven patients, and serial dilutions of the DNA isolated from these 
biopsies were subjected to PCR analysis. To evaluate the efficacy of PCR experiments, 
amplification of the mbr t(14;18)-positive SU-OHL-6 cell line cells serially diluted in normal 
mononuclear blood cells was performed. The experiments were evaluated if the 10's dilution 
W2S positive after 30 cycles. The quality of high-molecular weight DNA isolated, was 
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established by amplification of a 750 base pair (bp) fragment of the interleukin-3 (JL-3l gene in 
25 cycles for frozen tissue. This amplified product was visible upon ethidium bromide staining, 
indicating large amounts of amplified products (3,23). The quality of DNA isolated from 
paraffin-embedded tissue was reduced, as demonstrated by the results of the amplification of a 
300-bp and 750-bp fragment of the IL-3 gene in 40 cycles (3,23). In most samples, the 300-bp 
IL-3 fragment was detectable upon hybridization, whereas the 750-bp IL-3 fragment was 
absent. 
RESULTS 
Eight patients with t(14;18)-positive follicular NHL were evaluated for the presence of 
t(14;18)-positive cells in the circulation (peripheral blood and bone marrow) during first 
remission. In Table 1 lists data concerning the remission status and duration of these 
patients, as well as PCR results. 
Presence of t{14;18}-positive cells during first clinical remission. 
After initial treatment, six patients reached a complete remission and showed no 
clinical evidence of disease (NCED) and 2 patients responded partially to treatment and 
had clinical evidence of disease (CEO). In the' circulation of four patients with NCED, 
t(14;18)-positive cells were detected; in the other two patients, PCR was negative 
during first remission. In patients with CEO, one patient showed no t(14;18)-positive 
cells in the peripheral blood on all occasions tested, and the other patient had positive 
PCR's during first remission. Comparison of clinical status at the date of sampling with 
peR data showed the following results: t(14;181-Positive cells were detected in 15 
samples, while there was NeED in 13; and no t(14;181-positive cells were detected in 
18 samples, while there was CEO in four. 
Presence of t(14;18}-positive cells with respect to duration of first clinical remission. 
The remission duration is calculated for all patients 8 months from diagnosis (eight 
courses of CVP every 4 weeks plus or minus radiotherapy) until progression or the end 
of the observation period. The first-remission durations for three patients who relapsed 
during the observation period were 17, 17 and 78 months. The first-remission 
durations of the 5 patients in ongoing remission was 22,56,57,61 and 81 months. 
For these eight patients we also calculated the duration from the first PCR 
determination to clinical relapse or the last PCR determination. For the three patients 
with clinical relapse, the durations of peR follow-up were 10, 17 and 34 months. For 
the five patients in ongoing first remission the durations of peR follow-up were 20, 27, 
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33, 34 and 37 months. 
Circulating t(14; 18)-positive cells in individual patients. 
In the individual patients, we found a tendency that t(14;18)-positive cells were either 
present or absent in the circulation. This is not only true for the six patients with NeED 
who nearly always showed a positive peR (patient no. 2, three of three; 4, five of five; 
5, two of three; and 7, three of five) or a negative peR (patient no. 1, six of six; and 6, 
five of five). but also for the two patients with CEO, with patient no. 3 being positive 
(twO of two) and patient no. 8 being negative (four of four). Of the three patients who 
relapsed during the observation period, one was already positive during clinical 
complete remission (no. 4), one remained negative (no. 8), and one showed both 
positive and negative results during remission and was not tested after relapse (no. 7). 
In patient no. 7, t(14;18)-positive celis were detected 48 and 62 months after 
diagnosis; at 68 and 78 months, the amount of circulating t(14; 18)-positive cells was 
below the detection level, but reappeared with slightly increased frequency at 82 
months after diagnosis. Eighty-five months after diagnosis, a clinical relapse became 
evident. Figure 1 shows one peR experiment in which, in contrast to other 
experiments, no amplification product was seen at 62 months. In patient no. 3, 
t(14; 18)~positive cells were detected in all samples, except for the sample just taken 
after completion of chemotherapy. 
LN PB 
48 
PB 
62 
PB 
68 
PB 
78 
PB 
82 
Figure 1: 
peR experiment of patient no. 7. 
t(14;18)-positive cells were detected in 
the lymph node (LN) and peripheral 
blood (PS) samples (48 and 82 months 
after diagnosis). The amplified fragment 
is approximately 200-bp. 
DISCUSSION 
In this longitudinal study, we used amplification of the t(14;18) by peR to detect 
minimal residual disease in patients with stage III and IV t(14;18)-positive follicular NHL 
during first remission. In these patients, initial treatment was given in conventional 
dosages with the aim to reduce the disease as much as possible. 
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Table 1: Clinical characteristics and PCR results of patients with t(14;18)-positive follicular NHL at diagnosis and during follow-up. 
Patient Date of Stage Follow-up Sample 1(14;18) peR Clinical Clinical Remission Therapy 1m Mo 
no. Diagnosis (months) (fragment size) Status (months) 
1 11/87 IV 0 IN {pI +++ (160bp) 8xCVP, IFN·o IgM kappa 
27 PB NeEO NO NO 
33 PB NeeD NO NO 
40 PB NeED NO NO 
62 PB NeED NO NO 
64 PB NeEO 56 
BM 
2 6/87 IV 0 IN {pi +++ (220hp) 8xCVP, RT, IFN-o NO 
42 PB + NeED NO 
65 PB + NeED NO NO 
69 PB + NeeD 61 NO NO 
3 9/90 
'" 
0 LN {pi +++ (150bp) NO 
PB + NO NO 
1 PB + CEO 1xCVP 
6 PB + CEO 5xCVP NO 
8 PB CEO BxCVP 
10 PB + CEO RT NO NO 
30 P8 + CEO 22 NO NO 
4 2/89 IV 0 LN (pI + + + (235 bpI BxCVP IgM kappa 
8 P8 + NeED 8xCVP NO 
9 P8 + NeED 
BM + NeED 
11 P8 + NeED NO NO 
16 P8 + NeED NO NO 
26 P8 + NeED 17 NO 
31 P8 + CEO, relapse Surgery + + 
43 PB + CEO + + 
BM + NO 
6 7/86 III 0 IN {pi + + + (230 bpJ BxCVP, RT NO 
65 PB + NeED NO NO 
75 PB + NeED NO NO 
89 P8 NeED 81 NO NO 
6 8/87 III 0 IN {pI +++ (120bp) 
32 PB NeED 
45 PB NeeD 
52 PB NeED 
5. PB NeeD 
65 PB NeeD 
7 3/86 III 0 IN (f) +++ (200bp) 
48 PB + NeeD 
62 PB + NeED 
68 PB NeeD 
78 PB NeED 
82 PB + NeED 
85 CEO, nodal relapse 
8 6/89 III 0 IN {pI + + + (200 bpJ 
2 PB CED 
5 PB CED 
7 PB CED 
BM CED 
15 PB CEO 
18 PB CED 
21 PB CED 
25 PB CEO 
33 P8 CEO, progression 
3. PB CED 
---_._---_.-
Abbreviations: LN lymph node: (pi paraffin 
P8 
8M 
CED 
NCED 
CVP 
IFN-a 
RT 
1m 
Mo 
ND 
(1) frozen 
peripheral blood 
bone marrow 
clinical evidence of disease 
no clinical evidence of disease 
cyclophosphamide, vincristine and prednisone 
interferon-a 
radiotherapy 
immunological marker analysis 
morphological examination 
not determined 
+ + + PCR positive on diagnostic lymph node biopsy 
+ PCR positive upon hybridization 
8xCVP, RT IgM lambda 
ND ND 
ND ND 
ND ND 
ND NO 
57 ND NO 
8xCVP, RT, IFN-a IgM kappa 
ND ND 
ND ND 
ND ND 
ND NO 
78 ND ND 
Expectative 
8xCVP, RT, IFN-a ND 
4xCVP ND ND 
7xCVP ND ND 
ND ND 
ND NO 
IFN-a ND ND 
IFN-a ND ND 
IFN-a ND ND 
17 IFN-a NO ND 
Chlorambucil ND ND 
ND ND 
A method for the detection of minimal disease can be useful for two reasons: to 
establish the clinical extension of disease at diagnosis and after treatment and to 
predict clinical relapse. In such a sensitive method as PCR, one may expect positive 
reactions not only in patients with CEO, but also in patients with NCEO. We and others 
have shown that the latter is the case (3,23,24). Also in this study, in four of six 
patients with NCEO, t(1 4; 1 8)-positive cells remained detectable. In two of four 
patients, negative reactions were found in one of three and two of five time points. 
This indicates that the number of circulating t(14;18)-positive cells in these patients 
fluctuated around the detection level of peR. The finding of t(14;1S)-positive cells in 
the circulation of patients with NCEO is in agreement with observations in patients with 
localized disease (stage I and II), in whom we and others found circulating t(14;1S)-
positive cells both at diagnosis and after local radiotherapy in a high percentage of the 
patients (23,26). In two patients with NeED, the peR was negative, which means that 
either no t(14;1S)-positive cells were present or the frequency of these cells in the 
circulation was below the detection level. However, here we describe also a patient 
with CEO who repeatedly showed negative reactions. It is unlikely that interferon-a 
treatment in this patient caused the negative PCR results, because these results 
remained negative during nodal progression and after cessation of treatment with 
interferon-a. Also, shortly after the end of chemotherapy treatment, a negative reaction 
was found in patient no. 3, although nodal disease was clinically evident. Therefore, 
negative findings may occur not withstanding the presence of nodal disease, and these 
findings do not exclude the possibility of relapse or progression. 
Our data also indicate that there is no obvious correlation between PCR-
detectable t( 1 4; 1 S)-positive cells and the duration of first remission in patients with 
stage III and IV follicular NHL. Clinical remission duration of PCR-positive patients 
ranged from 17 to S1 + months, and of PCR negative patients from 17 to 65+ months. 
This is in agreement with the observation that circulating t(1 4; 1 8)-positive cells are also 
detectable in stage I and II patients for long times and may be explained by either the 
indolent course of disease or the assumption that the presence of t{14;18) may 
represent a premalignant status of the cell (23,24,26). The two patients with NeED 
and without PCR-detectable t(1 4; 1 8)-positive cells in the circulation showed an ongoing 
clinical complete remission. Further studies and longer follow-up durations may show 
that, in those few patients, a negative PCR finding has some prognostic value. 
So, our study shows that PCR for the detection of minimal residual disease in 
patients treated as described here is not clinically helpful. Besides the reasons 
mentioned here, one may also argue that spread of lymphoma cells in the circulation is 
not solely dependent on the number of lymphoma cells present in the body, but is a 
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characteristic of the individual lymphoma. In this study, we show a tendency that the 
number of circulating cells in a patient is rather constant, mostly either positive or 
negative during the observation period. In this respect, patient no. 8 is of importance, 
as she never showed a positive PCR reaction, not even at the time of clinical 
progression. If peR shows positive results, then the number of circulating t(14;18)-
positive cells is just above the detection level. In the two PCR positive patients who 
relapsed, no or a small increase of the intensity of the hybridizing bands was found. 
More precise quantitative methods are necessary to evaluate whether clinical relapse is 
accompanied by an increase in the number of circulating t(14;18)-positive cells (27). 
However, the factors that influence recirculation of lymphoma cells are largely 
unknown. 
A correlation between the presence of circulating t(14;18)-positive cells with the 
prediction of impending relapse has been reported for patients treated with bone 
marrow ablative therapy followed by autologous bone marrow transplantation. Disease-
free survival was markedly increased in patients without PCR-detectable t(14;18)-
positive cells in the graft (28-30). Disease-free survival was also markedly increased 
when no PCR-detectable t(14;18)-positive cells were found in the bone marrow after 
bone marrow transplantation (30). The patients who relapsed had PeR-detectable 
t(14;18)-positive cells in their bone marrow before clinical relapse occurred (30). 
Thus far, peR monitoring of patients with t(14;18)-positive follicular NHL treated 
by conventional therapy is questionable in the prediction of clinical outcome. However, 
monitoring seems to be highly justified in patients treated with bone marrow 
transplantation or other future treatment modalities aimed at cure. 
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CHAPTER 5 
Lymphomas with testicular localization show a consistent 
BCL-2 expression without a translocation (14; 18): A 
molecular and immunohistochemical study. 
A.C. Lambrechts, L.H.J. Looijenga, M.B. van 't Veer, B. de Jong, W. Timens and J.W. 
Oosterhuis. 
Submitted for publication. 
SUMMARY 
The presence of the BCL-2 protein was studied in nine non-Hodgkin's lymphomas (NHL) 
with testicular localization. A consistent presence of the BCL-2 protein was found. The 
chromosomal translocation (14; 18) was seen neither by cytogenetic analysis (n = 4) nor 
by polymerase chain reaction amplification and Southern blot analysis (n =9). 
Therefore, this translocation is not responsible for the presence of the BCL-2 protein in 
NHL with testicular localization. We suggest that the presence of the BCL-2 protein in 
these lymphomas is related to the differentiation stage of the B-Iymphocytes and/or 
may playa role in the pathogenesis of these lymphomas. The consistent finding of the 
BCL-Z protein in lymphomas with testicular localization may support the clinical 
observation that these lymphomas are a separate entity. 
INTRODUCTION 
Non-Hodgkin's lymphomas (NHL) localized in the testis are extremely rare. They may 
occur as a primary manifestation or in the context of dissemination of nodal NHL 
(secondary testicular NHL) (1-4). Thus far, there are no criteria to discriminate between 
these two. These NHL of the testis are usually diffuse large cell NHL according to the 
Working Formulation for lymphomas (1~4). The prognosis of NHL with testicular 
localization is poor, most patients die of disseminated NHL within two years. In 
addition, they show a specific pattern of metastases, e.g., extranodal sites such as the 
upper airways, central nervous system and bones are especially involved (2,3). 
The chromosomal translocation between the chromosomes 14 and 18 
[t(14q32;18q21)] is found in 60% to 85% of the follicular NHL and 20% to 30% of 
the diffuse large cell NHL (5-10). Due to the t(14;18) the B-cell lymphoma 2 (BCL-2) 
gene located on the long arm of chromosome 18 is juxtaposed to the joining (JH) 
region of the immunoglobulin heavy chain UgH) gene located on the long arm of 
chromosome 14 (11-14). This results in an enhanced expression of the BCL~2 gene 
which subsequently results in a disturbed programmed cell death (PCD), Le., a 
prolonged cell survival (15-19). 
In follicular NHL, diffuse large cell NHL and NHL of the gastrointestinal tract the 
BCL-2 protein is found using immunohistochemistry (20-25). Presence of the BCL-2 
protein is also reported in normal lymphoid cells and is demonstrated in precursor cells 
of all hematopoietic lineages, memory B-cells and plasma- and mantle zone- B-cells (26-
28). In nearly all follicular NHL, independent of the presence of the t(14;18), the BCL-2 
protein is present (20,21,23). In 22% to 80% of the diffuse large cell NHL the BCL-2 
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protein is found, also not restricted to those with the t(14;18) (20·22,24). NHL of the 
gastrointestinal tract, neoplasms in which t(14;18) occurs infrequently, show presence 
of the BCL·2 protein in about 50% of the cases (24,25). Thus the BCL-2 protein is 
found in normal lymphoid cells and in many different histological subtypes of NHL 
independent of the presence of the t(14;18). 
In the context that NHL with testicular localization show a separate clinical 
identity among NHl, we investigated the presence of the t(14;18) by combining 
cytogenetic analysis (n =4), polymerase chain reaction (peR) analysis and Southern 
blotting analysis (n=9). The presence of the BCL-2 protein was studied using 
immunohistochemistry on frozen tissue sections (n :;;;;;9). 
MATERIALS AND METHODS 
Samples: Tumor samples were collected in the Netherlands from 9 patients with NHL 
localized in the testis. The tumors were classified according to the Working Formulation for 
lymphomas by a panel of pathologists (29). Staging was according to the Ann Arbor 
classification (30). Representative frozen tissue sections were used for immunohistochemical 
and immunofluorescence analysis (9). 
Immunohistochemistry: Frozen tissue sections of 4 micron were fixed in acetone 
(100%) for 10 minutes. Endogenous peroxidase activity was blocked using 0.3% H2 0 2 in PBS, 
containing 0.2% BSA. Expression of the BCL~2 protein was studied using a mouse monoclonal 
antibody 8CL~2 100a (kindly provided by Drs. F. Pezzella and D.Y. Mason (21). Visualization 
was performed using an indirect peroxidase assay with a streptavidin-biotin conjugated goat 
anti~mouse immunoglobulin antibody as a second step. Hyperplastic lymph nodes were used as 
positive controls. 
Immunofluorescence: Surface marker analysis was performed by direct 
immunofluorescence with FITC~conjugated goat anti~human IgM, IgD, IgG, IgA and lambda 
serum and TRITC-conjugated goat anti-human kappa and lambda serum (Nordic Immunological 
Laboratories Tilburg, The Netherlands). Double staining was performed with TRITe-conjugated 
goat anti-human kappa plus FITC-conjugated goat anti-human lambda or with the FITC-
conjugated antibody against the heavy chain expressed by the malignant 8-cell plus TRITC-
conjugated anti-kappa or anti-lambda. 
Cytogenetic analysis: Cytogenetic analysis was performed on metaphase spread 
chromosomes of four cases according to standard procedures (31). The chromosomes were 
identified with G banding (GTG banding) and described according to ISCN 1991 (32). 
DNA extraction and Polymerase Chain Reaction analysis: High molecular weight DNA 
was isolated from frozen tissue sections of all NHL with testicular localization. DNA was 
digested with Hind 11/ and analyzed for t{14;18) and immunoglobulin heavy chain (lgH) 
rearrangement using Southern blotting and probing with 8CL-2 (12) and the joining region of 
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Table 1: Summary of the age of the patients, localization and stage of the disease at diagnosis. response to initial treatment, the 
localization of metastasis at relapse and data on histology of the nine NHL with testicular localization. Further, we present 
the results of Southern blot analysis for IgH rearrangement, polymerase chain reaction and Southern analysis for the 
detection of 1(14;181. Also, the immunohistochemical detection of the BCL-2 protein and the immunofluorescence 
detection of immunoglobulin heavy chain and light chain proteins are presented. 
3 
4 
, 
Case 
, 
2 
3 
4 
5 
6 
7 
8 
9 
Age In Stage localization at diagnosis' 
years 
52 I testis l 
78 I testis L 
74 
" 
testis R, lymph nodes pera-
aortal 
56 
" 
testis R, lymph nodes pars-
macal and para-aortal 
83 
" 
testis R, lymph nodes vena 
cava inferior and pare-aortal 
40 I tastis L 
64 I testis L 
66 I tastis 
81 I tastis R 
L = left, R = right 
CCR = clinical complete remission 
CNS = central nervous system 
Response to localization at relapse or Histology" 
treatment1 after progresslon3 
CCR spleen, liver, kidney, bone LBC 
marrow 
progression skin LBC 
CCR CNS LeG, PC 
CCR Lec, 18 
progression Waldeijar ring. lUng. sub· lBC,PC 
mandibular, supraclavicular 
CCR CNS LBC,IB 
CCR LBC 
lost for follow-up LBC,PC 
CCR LBC,IB 
. 
LBC = large B·cell lymphoma, PC = polymorph centroblastic, IB = immunoblastic 
G = germ line; R = rearranged 
IgH = immunoglobulin heavy chain protein 
IgL = immunoglobulin light chain protein 
Southern6 PCR BCl·2 IgHS fgll 
1(14:18) protein protein protein 
GIR - + I,M kappa 
G + I,M kappa 
GIR + I,M lambda 
GJR + I,M kappa 
GIR + I,M kappa 
GIR + I,M kappa 
GIR + I,M lambda 
GIR + I,M kappa 
GIR - + I,M lambda 
IgH allele (33). In addition, the polymerase chain reaction was used to detect small amounts of 
t(14; 181-positive cells. PCR primers were designed for the major breakpoint region (mbr 
(S'GGTGGTTTGACCTTTAGA 3'» of the BCL-2 gene and the consensus region oftheJH genes 
IS' TGAGGAGACGGTGACC 3')(91. As a control to DNA quality the interleukin-3 gene ofthe 
DNA was amplified in 25 cycles, as described (9). Forthe detection oft(14;18) a total of 0.5-
1.0 pg of DNA in a reaction volume of 25-50 pi was subjected to 30 cycles of PCR 
amplification using an automated Perkin-Elmer/Cetus DNA Thermal Cycler (Gouda, the 
Netherlands). In each experiment positive and negative controls were included. As positive 
controls different dilutions of DNA from a mbrt(14;18) positive cell line (SU-DHL-6) or DNA 
from a mcrt(14;18) positive lymph node biopsy was used. Amplified samples were analyzed as 
described using the BCL-2 and JH probes (9). 
RESULTS 
The age of the patient, the localization and the stage of disease at diagnosis, response 
to treatment, the localization of metastasis at relapse and the histological subtype of 
the non-Hodgkin's lymphoma localized in the testis are summarized in Table 1. 
Additional data concerning the results of Southern blotting analysiS for IgH 
rearrangements and PCR for t114;181 and the screening for BCL-2, immunoglobulin 
heavy (lgHI and light chain (lgLI proteins are also presented in Table 1. 
..... ! I I 
---,--):.f-- . 'ti_. i''''''------l l1-J''.·!:.'-
.,.- ! jo 
',,"""., I:: M " 
III . I I I 
-i--1IiU-· .. -(-.-~,-. ;-~-d-· -",j;l!!ll!itr---;~ 
• 
, 
• • 
" " " 
I I I 
----,--·.---.t~·!lI-1 -.c-. -\l:S-lt-i:-,t~-
" " 
-=-----jijlt-. -\*.:IiI\'I----------------
Figure 1: 
" 
A representative karyotype of one non-Hodgkin's lymphoma with 
testicular localization lease 3, Table 1 and Table 21. 
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Of the four NHL in which cytogenetic analysis was performed, the 
representative karyotypes are summarized in Table 2. Besides multiple chromosomal 
abnormalities, no translocation t(14;18)(q32;q21) was detected. The karyotype of case 
3 is presented in Figure 1. rn addition, none of the NHL with testicular localization, 
showed evidence for the presence of t(14; 18) by peR and Southern blot analysis. 
Immunological phenotyping of the NHL with testicular localization showed that 
all are B-cell NHL. Monoclonality of the B-cell population was demonstrated by the 
expression of either kappa or lambda in all biopsies. Monoclonality was confirmed by 
Southern blot analysis in eight of the nine NHL by the detection of a IgH gene 
rearrangement using a probe specific for the JH region. In case 2 monoclonality was 
not confirmed by the detection of a IgH gene rearrangement. This might be caused by 
the fact that the germ line and rearranged fragments were identical in size. The BCL-2 
protein was consistently present in the cytoplasm of all lymphoma cells of the NHL 
with testicular localization. A representative example is given in Figure 2. 
Table 2: 
3 
4 
5 
9 
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Representative karyotypes of four non-Hodgkin's lymphomas localized in 
the testis (cases 3, 4, 5, 9, Table 1). 
Description 
45, X, -V, deI(2)(p12p13)' add(3)(q26.1)' deI(4)(q22), deI(5)(q15q31), 
deI(6)(p24), de1(6)(q21 q23), add(7)(q22), deI(9)(p23), add(10)(p12), 
der(11 )(11 pter-> 11 q25::11 q25-> 11 q22::?), r(12)' i(17)(p1 0), i(17)(q 1O), 
add(19)(p13) 
49, dup(X)(p21 p22.2)' -V, deI(6)(q23), del (6)(q15)' +8, 
t(11;14)(p11;q11), +12, +13, del(14(q31), +18. 
88, XXyy, +Y, +Y, add(1)(q31)x2, -2, -2, -5, add(7)(q21)x2, i(7)(q10),-
8, add(8)(q24)x2, -9, -9, -9, -9, -10, -11, -11, del(11 )(q22q23), -12, -
14, -15, -16, -16, -17, -17, -17, -17, add(18)(q21)x2, -19, -19, 
+der(?)t(?;5)(?;q13), +der(?)t(?;17)(?;q21 )x2, + mar1, + 12mar. 
88, XXYY, add(1 )(p11), del(2)(p11.1)' -3, -4, add(6)(q15)' add(6)(q16)x2, 
+ 7, t(7; 19)(q11.2;q13), -11, -12, -13, -13, -15, -15, -17, 
add(19)(p13.1), -20, -22, +mar1x2, +4mar. 
Figure 2: A representative example of the immunohistochemical detection of the 
BCL-2 protein on frozen tissue sections of a non-Hodgkin's lymphoma 
with testicular localization (case 3, Table 1). 
DISCUSSION 
NHL localized in the testis are high grade malignant NHL and usually of B-Iymphocyte 
origin. They compromise approximately 1 % of all lymphomas and have a specific 
clinical course of disease. They metastasize to uncommon sites for other lymphomas, 
for instance the central nervous system (2,3). 
Cytogenetic analysis of four of the NHL with testicular localization revealed 
many different and complex chromosomal abnormalities but no chromosomal 
translocation (14;18) as found in other histological subtypes of NHL (5-10). In addition, 
we used PCR analysis, a technique able to detect one t(14;18)-positive cell out of 
100,000 normal cells, to evaluate nine of the NHL with testicular localization for the 
presence of t(14;18)-positive cells. No t(14;18)-positive cells were detected in these 
NHL. The presence of the BCL-2 protein in different histological subtypes of NHL 
without the presence of t(14;18) was the reason to evaluate the involvement of the 
presence of the BCL-2 protein in NHL with testicular localization as well (24,25). While 
the BCL-2 protein was present in normal lymphoid cells, no BCL-2 protein was reported 
in normal testis (26-28). Our data show the presence of the BCL-2 protein in all of the 
NHL with testicular localization studied. Thus in aU cases of NHL with testicular 
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localization we studied, the BCL~2 protein is consistently present without a t(14;18). In 
spite of the relatively small number of cases, this finding supports the clinical 
observation that NHL with testicular localization represent a separate entity. The 
presence of the BCL-2 protein may represent a differentiation stage of the B~ 
lymphocyte or a functional subpopulation of B~lymphocytes that preferentially localize 
in extranodal sites, for example the testis, and metastasize to other extranodal sites 
possibly explaining the aggressive behavior of these NHL. 
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CHAPTER 6 
Genomic organization of the translocations (8; 14) and 
(14; 18) in a new lymphoma cell line. 
A.C. Lambrechts, L.C.J. Dorssers, P.E. Hupkes, R. van Gurp, R. Baumgarten, A. 
Hagemeijer, M.B. van 't Veer and loP. Touw. 
Leukemia in press. 
SUMMARY 
We generated a new lymphoma cell line carrying the translocations (8;14) and (14;18) 
and studied the genomic organization and expression of the BCL-2 and MYC genes. 
PCR and Southern analysis showed that the breakpoints of t(14; 18) were located in the 
mbr of the BCL-2 gene and just 5' of JH6 in the IgH locus. The breakpoints of the 
t(8; 14) were located upstream of exon 2 in the non-coding region of the MYC gene and 
near the switch region of the IgH locus. Both IgH loci were involved in chromosomal 
translocations resulting in the absence of a functional B-cell receptor. Normal 8CL-2 
and truncated MYC transcripts were detected in these cells. The BCL-2 protein was 
expressed. 
INTROOUCTION 
Specific chromosomal translocations are consistently present in some hematological 
malignancies. The translocation (14;18)(q32;q21) is predominantly associated with 
follicular non-Hodgkin's lymphoma (NHL)' and is found in 50-85% of these lymphomas 
(1-4). In diffuse NHL the frequency of t(14;18) is about 20% (4-6). As a result of this 
translocation, the oncogene BCL-2, located on chromosome 18, is placed near the 
joining region (JH) of the immunoglobulin heavy chain genes (lgH) located on 
chromosome 14 (4,7-9). This translocation occurs as an aberrant V-D-J heavy chain 
joining and is thought to be an early event in the development of malignancy. The 
translocation usually results in increased BCL-2 protein expression (2,10). The latter 
has been linked to the prevention of programmed cell death (apoptosis) (11). 
The translocation (8;14)(q24;q32) is associated with 80% of the Burkitt 
lymphomas (BL) and has also been detected in other lymphomas, including diffuse large 
cell lymphomas (4,12). In t(8;14), the MYC oncogene located on chromosome 8 
translocates with divergent transcriptional orientation to the IgH locus on chromosome 
14. This translocation is thought to take place during heavy gene isotype switching 
(4,13). In the remaining 20% of BL, variant translocations involving the MYC gene and 
the kappa or lambda light chain constant region genes have been observed, resulting in 
respectively t(2;8)(p12;q24) and t(8;22)(q24;qll) (14,15). Also, these translocations 
usually result in an aberrant expression of the MYC oncogene (4,16). 
Histological progression of follicular NHL towards a leukemia with immunologic 
characteristics of early pre-B-cells has been reported. These leukemic blast cells carry 
both the t(14;18) and the t(8;14) (17-19). 
We present the cytogenetic analysis and genomic organization of a new cell line, 
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established from a bone marrow sample of a patient with an immunoblastic large cell 
lymphoma in which a t(14;18) and a t(8;14) coexist. Further, we analyzed the 
expression of both the BCL-2 and MYC oncogene. 
MATERIAL AND METHODS 
Case report:. A 70 year old female patient (OS) presented with a 5 week history of 
tiredness, weight loss and fever. Physical examination and CT scanning showed no 
lymphadenopathy and no spleen or liver enlargement. The leucocyte count at diagnosis was 5.4 
x 109 /L with 47% lymphocytes and 1 % blasts. The diagnosis of large cell immunoblastic 8-cell 
lymphoma was based on morphological criteria and immunological phenotyping of peripheral 
blood and bone marrow cells (20,21). Clinical improvement of only short duration was achieved 
after a first chemotherapy course. Two months after diagnosis, the disease manifested in the 
central nervous system and the patient died 2 months later. 
Immunological marker analysis: Immunological marker analysis was carried out on 
peripheral blood and bone marrow at diagnosis and at relapse. The marker analysis was 
performed by indirect immunofluorescence with the monoclonal antibodies C019, C020, C03, 
CD22, CD37, CD45, HLA-DR (Becklon Dickinson Sunnyvale, CA, USA), CD38, CD13, CD33 
(Coulter, Mijdrecht, The Netherlands). C010, C015, CDw65 (a gift from Dr. W. Knapp, Vienna, 
Austria) and C02 (lTK diagnostics, Uithoorn, The Netherlands) as a first step and flourescein-
isothiocyanate (FITC) conjugated goat anti-mouse immunoglobulin serum (Central Laboratory 
Blood Transfusion Service, Amsterdam, The Netherlands) as a second step (23). A polyclonal 
rabbit anti-terminal-deoxynucleotidyHransferase (TdT) serum was used combined with a goat 
anti-rabbit serum as a second step UTI( diagnostics, Uithoorn, The Netherlands). Direct 
immunofluorescence was performed with FITC-conjugated goat anti-human IgM, IgO, IgG, IgA 
and lambda serum and tetramethylrhodamine-isothiocyanate (TRITC) conjugated anti-human 
kappa and lambda serum (Nordic Immunological Laboratories, lilburg, the Netherlands). 
Expression of the BCL-2 protein was analyzed using cytocentrifuged cell preparations, 
both unfixed and fixed by acetone (10 minutes). Cell preparations of the cell line (OS) derived 
from the bone marrow of patient OS and the cell lines SU-OHL-6 and Res-50 (23), all carrying a 
t{14;18), were evaluated in an indirect immuneperoxidase assay using the BCL-2 100-a 
antibody (a gift from Drs. F. Pezzella and D.Y. Mason) (24) as the first step and a streptavidin-
biotin conjugated goat anti-mouse immunoglobulin serum as a second step. 
In vitro culture: Lymphoma cells were isolated from the bone marrow by Rcoll Isopaque 
(Nygaard, Oslo, Norway) centrifugation. The interface fraction containing the lymphoma cells 
was T cell depleted by E rosetting and Rcoll separation (25). Monocytes were removed by 
plastic adherence (25). The remaining cells (2 x 106 ) were placed in 10 ml serum free culture 
medium in a T25 flask (Greiner, Alphen aan de Rijn, The Netherlands) and incubated at 37°C in 
a humidified atmosphere of 5% CO2 , The cultures were replenished biweekly and cell 
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concentrations were adjusted to 2 x 105 celis/mi. A spontaneously proliferating cell line (OS) 
emerged from this culture, which has been propagated continuously for more than one year. 
Cytogenetic analysis: Cytogenetic analysis was performed on a 24 hrs culture of bone 
marrow cells at diagnosis and on the cell line OS, according to standard procedures. The 
chromosomes were identified with R banding. 
DNA extraction and Southern blot analysis: High molecular weight genomic DNA was 
prepared from the cell lines OS, SU-OHl-6 and an Epstein-Barr virus (EBV) transformed B cell 
line (EBV-B) according to standard protocols (26,27). Ten micrograms of DNA were digested 
with 20-30 units of restriction enzymes (Hind III, Hind III + Xba I, Hind III + Xho I, EcoR I, 
EcoR I + Xba I, EcoR I + Xho I and BamH I) under conditions recommended by the suppliers. 
DNA was size fractionated on 0.8% agarose gels and transferred to nylon membranes (Hybond 
N+, Amersham, 's-Hertogenbosch, The Netherlands). Hybridization of the JH and Cp region of 
the IgH gene, BCl-2 and c-MYC was performed according to standard procedures, using 32p_ 
labeled DNA probes radiolabeled by the hexamer primer method (26). The probes used were: a 
2.8 kb EcoR I - Sgl II fragment containing part of the joining gene region of the IgH gene (JH3-
JH6)(28). a 1.2 kb EcoR I fragment of the Cp region (291. a 2.5 kb EcoR I fragment containing 
the constant kappa light chain region (30), a 1.4 kb 8g1 II - Hind III fragment containing the 
constant lambda 2 light chain region (31) and a 2.8 kb EcoR I - Hind III BCl-2 fragment specific 
for the major breakpoint region (7). For c-MYC a 2 kb Pst I fragment 5' of exon 1 (MYC28S), a 
1 kb Pvu II fragment containing exon , (MYC256) and a 1.5 kb Cia I - EcoR I fragment specific 
for exon 3 (MYC285 and MYC256 are gifts from Dr. I.A. liard Offringa, leiden, the 
Netherlands). 
Polymerase chain reaction: Polymerase chain reaction (PCR) analysis of the major 
breakpoint region (mbr) t{14;18) was performed as described using the JH consensus and BCl-
2 primers (3). Also a JH6 specific primer (5' TCGGAACATGGTCCAG 3') was used in 
combination with the same SCl-2 primer (32). The JH consensus primer hybridizes with 
sequences in all six JH genes. The JH6 specific primer hybridizes with sequences located 122 
base pairs (bpJ downstream of the JH consensus hybridization site in JH6 (32). 
RNA extraction and Northern blot analysis: RNA was isolated from the cell-lines OS, SU-
OHl-6 and EBV-B and the original bone marrow sample from which the cell line OS was 
derived, using the standard guanidinium isothiocyanate, cesium chloride method (22). Ten pg of 
total RNA was loaded on a denaturing 1.2% agarose formaldehyde gel and blotted to 
nitrocellulose according to standard procedures (22). The probes used for BCl-2 and c-MYC 
hybridization were the same as mentioned above. Hybridization with a glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) probe was performed to provide an internal standard for 
Quantification of total mRNA (33). Expression levels for BCl-2 and c-MYC were estimated and 
normalized for GAPDH mRNA levels by scanning with a densitometer (Bio-Rad laboratories BV, 
Veenendaal, The Netherlands). 
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Table 1: Immunophenotypic and genotypic status of the lymphoma cells of the 
patient and the cell line OS. 
Immunological Marker Patient Cells 
CO2 
C03 
C019 
COlO 
C022 
C020 
C037 
C038 
C045 
C013 
C015 
C033 
COw65 
s-lgH 
c-lgH 
s-Ig kappa 
c-Ig kappa 
s-Ig lambda 
c-Ig lambda 
HLA-OR 
TdT 
BCL-2 
C kappa genes 
C lambda genes 
Abbreviations: 
-
-
+ 
+ 
NO 
-
NO 
+ 
NO 
-
-
-
-
-
-
-
-
-
-
+ 
-
NO 
NO 
NO 
NO = not determined 
+ = positive 
- = negative 
Cell line 
-
-
+ 
+ 
-
-
+ 
NO 
+ 
-
-
-
-
-
-
-
-
-
-
+ 
-
+ 
deleted 
rearranged 
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RESULTS 
Immunological marker analysis. 
The cell line OS and the primary lymphoma cells express identical immunophenotypes 
(Table 1). The presence of the B-cell marker C019 and the absence of T-cell (C02, 
C03) and myeloid (C013, C033) antigens is consistent with the B-cell origin of this 
tumor. The BCL-2 protein is expressed in the cell line OS (Figure 1). 
1A 
Figure 1: 
1B 
Immunohistochemical detection of BCL-2 protein expression (A) and a 
negative control (B) on cytocentrifuged cell preparations of the cell line 
OS. 
Cytogenetic analysis. 
The bone marrow sample taken at diagnosis showed the following karyotype: 48, XX .. 
t(1 ;6)(q12;q26)' add (2)(q37), + del (7)(q21 q32), t(8;14)(q24;q32)' + inv 
(12)(p12.3q24), der (13) t(1 ;13)(q12;p12), t(14;18)(q32;q21), del (20)(p11 p13)' + 
ace. The cell line OS expresses the same cytogenetic abnormalities (Figure 2), 
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Figure 2: Karyogram of the large cell lymphoma cell line DS. Arrow heads indicate 
the derivative chromosomes of t(8; 14). Asterisks indicate the derivatives 
of t(14;18). The karyotype is described according to ISCN 1991 (41). 
Genomic organization of the breakpoints on chromosome 8,14 and 18. 
PCR with the two mbr-t(14;18) primer sets (BCl-2/JH; BCl-2/JH6) gave rise to 
amplified, breakpoint specific products (Figure 3 lanes 4 and 5 respectively). The 
fragment size of the peR product generated with a JH6 specific primer is 250 bp 
(Figure 3, lane 5), which indicates that the breakpoint is located just 5' of the JH6 
gene. The 120 bp size reduction of the peR product generated using the JH common 
primer confirms the localizatior. of the breakpoint within the JH gene (Figure 3, lane 4). 
The presence of the mbr-t(14;18) translocation in this cell line was also detected using 
restriction enzyme analysis and Southern blotting. BCl-2 hybridization of genomic DNA 
from the cell line OS, digested with Hind III, showed a germ line fragment of 4 kb and 
rearranged fragments of 3.5 kb and 7 kb representing the translocation and the 
reciprocal translocation (Figure 4 lane BCl). The 7 kb fragment also hybridized with the 
JH probe and represents most probably the reciprocal translocation (Figure 4 lanes Bel 
and JH). 
Restriction enzyme analysis and Southern blotting revealed that the breakpoint 
on chromosome 8 was located between the Xho I site in exon 1 and the Xba I site in 
intron 1 (Figure 5, germ line chromosome 8 and Table 2). EcoR I + Xho I and Hind III 
+ Xho I digested DNA from the cell line OS showed only germ line fragments after 
hybridization with MYC285 probe (Table 2). EcoR I + Xba I and Hind III + Xba I 
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Figure 3: 
PCR analysis of genomic DNA derived 
from the cell line OS (lane 4+ 5) and 
from serial dilutions of SU-DHL-6 cells 
in normal cells (lanes 1-3). In lane 5 the 
result from the amplification of genomic 
DNA from the cell line OS with the JH6 
specific and the BCLM 2 primer is shown 
(250 bpi. The amplified products 
generated with the JH consensus and 
the same BCL-2 primer are presented in 
lane 4 (130 bpi for the cell line OS and 
in the lanes 1 to 3 for the SU-DHL-6 
dilutions (10" to 1 0.5) (235 bpi. Blots 
were hybridized to both the BCL-2 and 
JH probe. At the left, the position of the 
size marker PhiX DNA digested with 
Hae III is depicted (in base pairs). 
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Figure 4: 
Genomic DNA from the cell line OS 
digested with Hind JIJ was hybridized 
with three different probes, BCL-2 (lane 
BCL), JH3-JH6 (lane JH) and MYC285 
(lane MYC). Translocations are marked 
by arrow heads, for t(14;181 see lane 
BCL and for t(8; 14) see lane MYC. 
Germ line fragments are marked by G. 
The size marker indicated on the left 
correspond to the 23.1, 9.4, 6.6, 4.4, 
2.3 and 2.0 kb fragments of lambda 
DNA digested with Hind III. 
= 
digested OS cell line DNA showed germ line fragments and translocated fragments of 
respectively 10 and 5.5 kb after hybridization with MYC285 and MYC256 probes 
(Table 2). Hybridization with the MYC exon 3 probe to EcoR I + Xba I and Hind III + 
Xba I digests showed only germ line fragments (Table 2). In EcoR I + Xho I and Hind III 
+ Xho I digests germ line fragments and additional translocated fragments of 
approximately 7 kb and 9.5 kb were seen respectively (Table 2). 
Hind III digests revealed a 5.5 kb and a 7 kb JH hybridizing fragment but no 11 
kb germ line fragment indicating that both JH genes were non-germ line and were 
Figure 5: 
E H XhXb E H gorm line ohr $. 
! ! ~! ! 
2 1 kb ~6 
3 
;3 
Genomic organization of the germ line 
c-MYC (chromosome 8) and Ig heavy 
chain (chromosome 14) loci and the 
t(8; 1 4). 80th the translocation and the 
E H Xh 8 H Xb 
germ Une chr 14 JH 
Xh H 
~ I 
«8;14) (V)DJ 1 
Xb E 
I~I 
2 3 
s, 
H 
I 
E E E 
C, 
E 
I 
reciprocal translocation (8;14) are 
schematically presented. Restriction 
endonuclease sites as well as the 
different probes used (JH =JH3-JH6, 
Cp, MYC285, MYC256, MYC exon3) 
are shown. The restriction endonuclease 
sites: 8 = 8g1 II, H = Hind III, E = 
EcoR I, X = Xho I and X = Xba I. 
Table 2: Localization of the breakpoint on chromosome 8. 
Digests MYC285 probe MYC exon 3 probe 
fragment size fragment size 
EcoR I + Xho I 7 kb (germ line) 5 kb (germ line) + 7 kb 
EcoR I + Xba I 8 kb (germ line) + 10 kb 4 kb (germ line) 
Hind III + Xho I 2.5 kb (germ line) 8 kb (germ line) + 9.5 kb 
Hind III + Xba I 3.5 kb (germ line) + 5.5 kb 7 kb (germ line) 
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either rearranged or involved in a translocation (Figure 4 lane JH). The 5.5 kb JH 
containing fragment is exclusively coupled to the 5' region of c-MYC as a result of the 
t(8;14) (Figure 4 lanes JH and MYC). The 7 kb JH containing fragment hybridized with 
the BCL-2 probe as a result of the t(14;18) (Figure 4 lanes JH and BCL). CII hybridizing 
fragments were not detected in the cell line DS, but were readily detected in the IgM 
expressing control cell lines, SU-OHL-6 and EBV-B, indicating that both CII loci were 
deleted in the cell line OS. 
mRNA expression of the c-MYC and BCL-2 oncogene. 
MYC and BCL-2 mRNA expression was analyzed in the cell line OS and the bone 
marrow sample from which the cell line OS was derived. The MYC mRNA detected 
after hybridization with the exon 3 probe in the cell line OS was approximately 0.4 kb 
shorter than 2.4 kb MYC mRNA in the control cell lines SU-OHL-6 and EBV-B (Fig 6). 
The bone marrow sample from which the cell line DS was derived contained an 
identical 2.0 kb MYC mRNA (data not shown). Densitometric analysis showed a 4-fold 
increase in the quantity of MYC RNA in the cell line OS in comparison to the EBV-B cell 
line. No enhanced MYC expression was detected in comparison to the SU~DHL-6 cell 
line. In the cell line and bone marrow sample from OS two normal 8.5 and 5.5 kb BCL-
2 mRNA transcripts were detected (data not shown). 
Figure 6: 
MYC mRNA expression, detected by 
hybridization with MYC exon 3 probe, 
of the cell lines SU-OHL-6 (SU), EBV-B 
(B) and OS. The lower panel shows the 
GAPOH control. At the right the 
location of 18 S ribosomal RNA is 
indicated. 
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DISCUSSION 
We described a cell line (OS) with the translocations (8;14) and (14;18). Expression of 
B-cell specific markers (CD19, CD10, CD37) and the absence of TdT expression 
suggests that the immunophenotype of the cell line, which was identical with the 
original lymphoma, represents that of a relatively mature 8-cell. Expression of other B-
cell specific markers (CD20, CD22) could not be detected. Differential expression of S-
cell specific antigens is seen in cell lines, non-Hodgkin's lymphomas and chronic 
lymphocytic leukemia (34). The relatively mature appearance of the S-cell line is further 
strengthened by the observation that the kappa genes were deleted and the lambda 
genes were rearranged which is a late event in 8-cell development. No expression of 
surface- or cytoplasmic- immunoglobulin heavy and light chain proteins was present. 
Deregulation of IgH protein expression is in line with the cytogenetic data which 
showed that both chromosome bands 14q32 were involved in chromosomal 
translocations, namely t(8;14) and t(14;18) and that both IgH loci were possibly 
altered. Restriction enzyme- and PCR- analysis further confirmed that both the IgH loci 
were involved. 
The breakpoints involved in the t(14;18) were localized by the primers used for 
PCR and occurred in the mbr region of the BCL-2 gene and just 5' of JH6. Restriction 
enzyme analysis of genomic OS DNA showed the translocation (3.5 kb fragment) as 
well as the reciprocal translocation (7 kb fragment) after hybridization with a BCL-2 
probe. In contrast, comigration with JH could only be detected for the 7 kb fragment 
and not in the 3.5 kb fragment. This is most likely due to a lack of hybridization to a 
short JH homologous region. This is in agreement with the observation that sequences 
located downstream of the JH genes on chromosome 14, the CJl genes, were deleted 
in the cell line OS. Likewise, the faint SCL-2 hybridization signal of the 7 kb fragment 
may be explained by a short mbr BCL-2 homologous region in the reciprocal 
translocation. BCL-2 mRNA expression was detected in the cell line and the bone 
marrow sample derived from patient OS (35). BCL-2 protein expression was detected in 
the cell line OS. 
Deregulation of the MYC oncogene was caused by a t{8;14). One rearranged 
Hind III fragment hybridizing with probes specific for the 5' part of the MYC gene (exon 
1) and the JH gene of the IgH locus was identified (Figure 4). Therefore, a Hind III site 
must be located just 5' of the JH gene which implies that rearrangement of at least the 
D-J genes and most probably V-D-J genes must have taken place. If the latter is the 
case then this (8;14) translocation most probably occurred during heavy chain isotype 
switching. The reCiprocal translocation, containing the MYC coding exons 2 and 3, 
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Table 3: Characteristics of the cell lines with t(8;14) and t(14;18). 
Cell Line 
Origin 
Reference 
Translocation 
t(8;14) 
t(14;18) 
C019 
COlO 
TdT 
s-lgH 
c-lgH 
s-lgL 
c-lgL 
BCL-2 mRNA 
MYCmRNA 
BCL-2 protein 
C kappa genes 
C lambda genes 
Abbreviations: 
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380 SU-OUL-S Ros-SO OS 
acute Iympho- lymphoblastic acute Iympho- immunoblastic 
blastic lymphoma blastic lymphoma 
leukemia leukemia 
38 37 23 
t(8;14), t(8;14;18) t(8;14;18) t(8;14), 
t(14;18) t(14;18) 
MYC germ line 5' of MYC NO exon 1 or 
in~ron 1 of 
MYC 
NO mcr mcr mbr 
NO NO + + 
+ NO - + 
+ NO - -
-
NO IgM -
- NO - -
- NO kappa -
- NO - -
NO - NO normal 
NO normal NO truncated 
NO 
- + + 
deleted NO NO deleted 
rearranged NO NO rearranged 
+ positive 
- :;;:;; negative 
NO :;;:;; not determined 
mbr = major breakpoint region of the BCL-2 gene (8,9). 
mer:;;:;; minor cluster region of the BCL-2 gene (40). 
could not be linked to JH and Cp sequences of the IgH locus (36). The IgH enhancer, 
located between the JH and switch (Sp) region, could be present in the t(8;14) or the 
reciprocal t(8;14). This enhancer or other IgH regulatory elements are involved in the 
expression of the truncated MYC mRNA. The expression level of the truncated MYC 
mRNA was about the same as the expression level of normal MYC mRNA in the cell 
line SU-OHl-6 and increased in comparison to the EBV-8 cell line. The truncated mRNA 
contained all coding sequences, thus expression of normal MYC protein(s) may be 
expected. In our case a deregulated MYC expression may have contributed to the 
malignant clinical behavior and the spontaneous growth in vitro. 
Coexistence of t(8;14) and t(14;18) has previously been reported for 3 cell lines 
(23,37,38) and approximately 8 patients (for review see 23,39). The characteristics of 
these 3 cell lines (380, SU-OUL-5, ROS-50) and the cell line OS are presented in Table 
3. In the cell lines, SU-OUL-5 and ROS 50, a three way translocation t(8;14;18) was 
found (Table 3)(37,23) Only in the cell lines OS and 380 the translocations (8; 14) and 
(14;18) were detected (Table 3)(38). In agreement with our observation in the cell line 
OS, the cell line 380 did also not express surface and cytoplasmic immunoglobulins and 
thus no 8-cell receptor. In the cell line OS the breakpoint on chromosome 8 was located 
within the MYC gene, whereas in the cell line 380 no rearrangement of the MYC gene 
was detected. Thus only in the cell line OS an aberrant MYC mRNA was detected. 
In conclusion, our cell line is an addition to a scarce panel of cell lines with the 
translocations (8;14) and (14;18). These cell lines may be used for further studies 
aimed at the involvement of these translocations and the absence of a functional 8-cell 
receptor in deregulating cell growth and maturation in lymphomas. 
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CHAPTER 7 
Discussion and perspectives 
1. Markers for the detection of minimal residual disease in patients with non-Hodgkin's 
lymphoma. 
1.1 CLINICAL RELEVANCE OF MINIMAL DISEASE DETECTION IN NON-HODGKIN'S LYMPHOMA. 
This thesis describes the application of the polymerase chain reaction (peR) in the 
detection of minimal (residual) disease in patients with non-Hodgkin'S lymphoma (NHL), 
especia1Jy follicular NHL characterized by the chromosomal translocation t(14;18) 
[t(14;18)]. This translocation provides a unique DNA sequence for these NHL cells and 
can be used as a target for peR. Detection of small numbers of NHL cells is important 
for accurate staging of the disease at initial diagnosis and for monitoring the course of 
the disease during and after therapy (1). We investigated the significance of the 
presence of t(14;18)-positive cells in the peripheral blood and bone marrow of patients 
with follicular NHL with respect to the stage of disease at diagnosis and the remission 
status and remission duration after (initial) treatment. 
1 .2 THE CHROMOSOMAL TRANSLOCATION T(14;18) AS MARKER FOR NON-HODGKIN'S LYMPHOMA 
CELLS. 
Even though the use of t(14;18) as a clonal marker for NHL and in the study of minimal 
residual disease (MRD) is very attractive, a number of limitations should be considered. 
i) The translocation t(14;18) is found in 60% to 85% of follicular NHL (2-4) and in 20-
30% of diffuse large cell NHL (5). In NHL the t(14;18) appears present in all lymphoma 
cells and can, therefore, be used as a clonal marker. Thus, the t(14;18) can be used as 
a marker in a substantial proportion of NHL patients. 
ji) Further, t(14;18) can be found in other 8-cell malignancies, including hairy cell 
leukemia (6). acute lymphoblastic leukemia (7,8) and multiple myeloma (9). In these 
cases t(14;18) has been demonstrated by cytogenetic analysis. In Hodgkin's disease 
t(14;18) has been demonstrated in 30% of the patients and is thought to occur in 
Reed-Sternberg cells or in polyclonal expanded B-cells (10). In Hodgkin's disease, 
however, t( 14; 18) is present in an extremely low proportion of the ce1Js and can only 
be demonstrated with very sensitive techniques as peR. The presence of t(14;18)-
positive cells in Hodgkin's disease and in a variety of 8-cell malignancies would suggest 
that t(14;18) is a relatively common event in 8-cell development. In Hodgkin's disease 
t(14;18) is not a clonal marker and not suitable for detection of MRD. In the other 
cases t(14;18) is a clonal marker and may be used for the detection of MRD. 
iii) In addition, t(14;18) may also appear in benign lymphoid disorders without 
progression to NHL (11-13). In benign lymphoid tissues the t(14;18)-positive cells are 
also present in extreme low numbers and can be detected with peR only. In these 
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conditions approximately one t( 1 4; 1 8)-positive cell per 105 normal cells was estimated 
to be present. In these cases t(1 4; 18) is not a clonal marker and not suitable for 
detection of MRD. 
iiii) In peripheral blood and bone marrow more than one type of t(14;1S) may be found, 
while the lymph node biopsy of the patient discloses only a single t(14;18) (14). As a 
matter of fact t(14;1 8)-positive cells not related to the original NHL are detected due to 
the extreme sensitivity of peR. Therefore, the presence of t(14;1S)-positive cells in 
peripheral blood and bone marrow from NHL patients per se is not sufficient to 
conclude that MRD is present. For example, a significant number of patients with 
follicular NHL (7 of 44 patients (14)) showed evidence of two coexisting t(14;18) with 
different breakpoints in peripheral blood samples taken in remission (14). In the lymph 
node biopsy from 5 of these 7 patients only one of the translocations could be 
demonstrated. Obviously, only the t(14;18) found in both the lymph node biopsy and in 
the peripheral blood of the patient can be used as a clonal marker for NHL. For this 
reason it is necessary to provide evidence that the t(14;1 8)-positive cells in peripheral 
blood and bone marrow are identical to the t(14;1 8)~positive cells in the lymph node 
biopsy by showing that the generated t(14;18)-specific peR products have the same 
size (chapter 2 figure 1, chapter 3 figures 1 and 2, and chapter 4 figure 1). Another 
possibility to provide this evidence is to determine the DNA sequence of the breakpoint 
region. This DNA sequence is most probably unique to each translocation and therefore 
more specific than the size of the t(14;18)-specific peR fragment. However, DNA 
sequencing is cumbersome and thus not attractive to apply on a routine basis. 
In the studies described in this thesis we have taken these points into account. The 
study deals with the detection of t(14;1S}-positive cells in peripheral blood and bone 
marrow from patients with follicular NHL as a minor lymphoma cell population. To 
reduce the possibility that these t(14;1S)-positive cells were not related to follicular 
NHL, the t(1 4;18) was used as a marker only in patients whose diagnostic lymph node 
biopsies were proven to be positive for t(14;18). The size of the t(14;18)-specific peR 
products from the diagnostic lymph node biopsy and from peripheral blood and bone 
marrow samples were identical in individual patients. 
1.3 CLINICAL RELEVANCE OF THE PRESENCE OF T(1 4;1 S)-POSITIVE CELLS IN PERIPHERAL BLOOD 
AND BONE MARROW. 
The use of peR in the detection of MRD in t(14;18)-positive follicular NHL provides a 
100 to 1,000 fold increase of the sensitivity of the detection of NHL cells in 
comparison to conventional techniques (chapter 2). We evaluated peripheral blood and 
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bone marrow negative for NHL cells according to conventional techniques, whereas 
t(14;18)-positive cells were detected with peR (15-18, chapters 2, 3 and 4). It is, 
however, important to assess the clinical relevance of the presence of t(14;18)-positive 
cells detectable by PCR only, i.e. in different clinical stages at diagnosis and after 
therapy. 
We evaluated the presence of t(14;18)-positive cells in patients with stages I and II 
disease. These patients are usually treated with involved field radiotherapy only. This 
treatment may result in longstanding clinical complete remissions and possibly even 
cure. The disease free survival for these patients is better than for patients with more 
advanced disease (19-22). Translocation t(14;18)-positive cells were frequently found 
in peripheral blood and bone marrow from patients with stages I and II follicular NHL at 
diagnosis and after therapy, whereas no clinical symptoms of disease were evident (15, 
chapter 3). Thus, the results obtained by evaluation of the presence of t(14;18)-
positive cells in peripheral blood and bone marrow of these patients using PCR indicates 
that follicular NHL is often a disseminated disease regardless the clinical staging. 
Despite the presence of t(14;18)-positive cells in these patients, some of these patients 
reach longstanding clinical complete remissions and possibly even cure (chapter 3). It is 
possible that in these patients the peR detectable t(14;18)-positive celis do not 
represent NHL cells. Instead they could represent pre-malignant cells carrying the 
translocation without additional cellular changes which are thought to be necessary for 
progressive malignancy (16,23). Apparently, peR detection of t(14;18)-positive cells in 
peripheral blood and bone marrow of patients with stages I and II follicular NHL has no 
or limited clinical relevance. 
We also evaluated the presence of t(14;18)-positive cells during remission in patients 
with stages III and IV follicular NHL, treated with conventional chemotherapy. Although 
most patients respond to treatment, at some point the disease recurs and the patients 
ultimately succumb from relapse of NHL (21,22). In peripheral blood of patients in 
(first) clinical complete remission t(14;18)-positive cells were frequently present, i.e., in 
approximately 55% to 85% of the patients (14,16-18, chapters 2 and 4). In patients 
with clinical signs of disease t{14;18)-positive cells were frequently, but not always, 
found in peripheral blood and bone marrow (17, chapters 2 and 4). Similar to the 
results in stage I and" patients, the presence or absence of t(14;18)-positive cells 
during remission in stage III and IV patients treated with conventional therapy does not 
correlate with the probability of relapse. This observation is in agreement with the 
report of Price et. a/. that t(14;18)-positive cells are detected in the circulation of 
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patients in long term remission from follicular NHL using peR (16). As stated in the 
previous section, these observations support the view that the event of the 
translocation itself may not be tumorigenic. Thus, peR detection of t(14;1S)-positive 
cells in peripheral blood and bone marrow of patients with stages III and IV follicular 
NHL has no or little clinical relevance. 
Of particular interest are t(14;1S) peR results obtained in patients treated with 
autologous bone marrow transplantation (ABMT). PCR was used to detect t(14;18)-
positive cells in bone marrow harvested for ABMT before and after ex-vivo purging (24-
28). The presence of residual t(14;18)-positive cells has been demonstrated in nearly all 
autologous bone marrow transplants before ex-vivo purging (17,24,25,27). In 50% to 
86% of the grafts residual t(14;18)-positive cells could still be demonstrated after ex-
vivo purging (24,27). Contradictory results have been reported with respect to PCR 
detection of t(14;18)-positive cells and disease free survival (24,27,28). A significantly 
better disease free survival was reported in one study if the graft was negative for 
t(14;18) (24). In addition, the correlation between the presence or absence of residual 
t(14;1S)-positive cells in the bone marrow after ABMT with disease free survival was 
studied (27,29). Again, contradicting results have been reported. A strong correlation 
between the absence of t{14;18)-positive cells and disease free survival was 
demonstrated. No relapse was seen in 58 patients with no PCR detectable t(14;18)-
positive cells in the bone marrow after ABMT, while a relapse appeared in 25 of 35 
patients with PCR detectable t(14;18)-positive cells consistently present in the bone 
marrow after ABMT (29). In another study no correlation could be demonstrated 
because in the bone marrow of all but one patient t(1 4;1S)-positive cells were detected 
after bone marrow transplantation (27). These data indicate that confirmatory studies 
as well as longer follow-up are necessary to establish the prognostic value of peR 
determination of t(14;1S) in patients treated with bone marrow ablative therapy. 
In conclusion, the usefulness of t{14;1S) as a marker for the detection of MRD in 
patients with t(14;18)-positive follicular NHL may depend on the choice of therapy. The 
application of extraordinarily sensitive techniques for detection of residual lymphoma 
cells is particularly useful to assess the level of tumor cell elimination and distinguish 
between complete and near complete remissions. While our and other studies show 
that there is no correlation between the presence or absence of peR detectable 
t(14;18)-positive cells in peripheral blood and bone marrow with the stage of disease, 
remission status and remission duration in patients treated with conventional therapies, 
in patients treated with high dose therapy and ABMT the presence of t(14;18)-positive 
87 
cells in the graft or in the bone marrow after ABMT may predict decreased disease free 
survival. It is possible that peR for the detection of t{14;18)-positive cells may become 
a useful tool if patients with follicular NHL are treated with therapeutic modalities aimed 
at cure, e.g., bone marrow transplantation, new chemotherapeutic agents, interleukins, 
monoclonal antibodies or combination modalities. In these situations, precise 
quantitation of residual t{14;18)-positive cells by competitive peR may contribute to a 
better understanding of the possible importance of the numbers of t(14;181-positive 
cells in peripheral blood and bone marrow with respect to remission duration and the 
efficiency of different treatment approaches (30). 
1.4 THE REARRANGEMENT OF THE IMMUNOGLOBULIN HEAVY CHAIN GENE AS A MARKER FOR NON-
HODGKIN'S LYMPHOMA CELLS. 
As discussed in section 1.1, t(14;18) is not a clonal marker for 15% to 40% of 
follicular NHL. For follicular NHL without the t(14;18) and for B-cell malignancies in 
general rearranged alleles of the immunoglobulin heavy (lgH) and light (lgL) chain genes 
can be used as a clonal marker. Rearrangement of the variable (V), the diversity (0) and 
joining (J) segments of the IgH gene and rearrangement of the V and J segments of the 
IgL gene create a unique immunoglobulin protein specificity. Furthermore, the addition 
of several bases during the assembly between these segments augments the variability 
of the DNA sequences in the rearranged Ig gene (31,32). Using PCR, the V-D-J 
sequences of the rearranged IgH gene can be amplified in vitro by choosing primers 
homologous to known V and J common sequences (33,34). The PCR product 
generated in this way is unique for the (malignant) 8-cell. This implies that the V-O-J 
sequence is patient specific, and can be used as a marker for NHL. For each malignant 
8-cell clone a specific probe has to be created which may subsequently be used to 
study MRO in that particular patient. IgH gene rearrangements have been detected 
successfully with peR in acute lymphoblastic leukemias, chronic lymphocytic leukemias 
and multiple myelomas (34-43). Also the amount of neoplastic cells has been quantified 
using the rearranged IgH gene as a clonal marker (34,39-44). In analogy, the rearranged 
IgH gene may also be used for the detection of minimal residual disease in B-cell NHL. 
So far, only few studies have been published (34,35,45-49). 
We investigated the applicability of the use of the rearranged IgH gene as a clonal 
marker in intermediate and high grade malignant 8-cell NHL. In these lymphomas the 
t(14;18) is present in only 20% to 30% of the cases and detection of minimal disease 
seems to be more clinically relevant than in follicular NHL. About 80 percent of these 
patients, according to evaluation with conventional techniques, may attain clinical 
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complete remissions following conventional chemotherapy. Approximately half of these 
patients have recurrences of NHl within 2 years, the others appear cured. The 
possibility to improve the detection of residual NHl cells may be of importance for 
monitoring the response to therapy, establishing the quality of the remission and 
identifying patients with a high probability of relapse. 
V-O-J peR was applied on a series of intermediate and high grade malignant NHl 
{n = 19}. A distinct IgH gene rearrangement was detectable on Southern blots using a J 
probe. Amplification of the V-D-J sequences was attempted with V family-specific 
primers in combination with a consensus J primer. The V family-specific primers were 
chosen in the leader sequence or the framework 1 region of the IgH gene. The results 
of these initial experiments may be divided in three different patterns of generated peR 
products: 
a) A specific PCR product was obtained with a single V family-specific primer in 30 
cycles in approximately 20% of the cases (n;;;;;:4). With other V family-specific primers 
no significant PCR products were detected. 
bl None of the V family-specific primers resulted in the production of a abundant peR 
product at the standard number of cycles (n;;;;;: 1 0). In most reactions peR products 
were detectable upon hybridization. 
cl None of the V family-specific primers resulted in the generation of peR products 
detectable upon hybridization at the standard cycles conditions although amplification 
of a different target (the interleukin-3 gene) was efficient (n = 5). 
In summary, our results so far have pointed at two technical problems: i) low recovery 
of specific PCR products after amplification of V-O-J sequences (36-39,45-48) and ii) 
difficulties in providing conclusive evidence that the generated markers were specific 
for the IgH gene rearrangement of the NHL. 
ad i) The absence of a specific peR product in approximately 80% of the cases 
strongly suggest that mismatches between the primer and the target sequences affect 
the efficiency of the amplification reaction (36,46,49,50). Variable success rates have 
been reported applying V-O-J PCR for different B-cell neoplasms (34,36,41,42,44,46). 
The highest success rate is reported for All and ell and varies between 80% and 
100% 134,36,41,42,44,46), whereas the success rate for lymphomas seems 
dependent on the histological subtype and varies between 17% to 67% (46,49). Low 
success rates were also attributed to primer mismatches in these reports. An additional 
complicating factor in NHl appears to be the presence of substantial amounts of oligo-
or polyclonal B-cells in the lymph node biopsy. Despite their under-representation in the 
biopsy, they will contribute to the amplification reaction and even dominate the peR 
89 
products if the IgH gene rearrangement is not efficiently amplified. Strategies to 
improve the recovery of the presence of the wanted target most likely have to deal 
with the primer mismatches and the presence of non-malignant B-cells. Possible 
modifications are: 
a) Amplification of serial dilutions (up to 10·') of DNA. If the lymphoma cells constitute 
a substantial percentage of the total B-cell population, as is suggested by the Southern 
blot analysis, the polyclonal normal B-cells will then fall under a critical threshold and 
will not give rise to peR products. 
b) Additional primers may be selected for each V family in the conserved domains or 
even V consensus primers for the framework 2 and 3 regions of the IgH gene. 
Furthermore, to reduce the number of amplification reactions, the V family used in the 
IgH gene rearrangement of the NHL may be established by Southern blot analysis. 
c) Target enrichment may be achieved by microdissection of lymphoma tissue (51). 
Alternatively, the IgH gene rearrangement may be isolated after size fractionation, using 
restriction endonucleases, from agarose gels and used as target for V-D-J sequence 
amplification. Its position in the gel is established by Southern blot analysis. 
d) RNA may be isolated from the lymph node biopsy which can be subjected to RT-PCR 
using 3' primers specific for the constant region of the 19H gene. At the 5' end either V 
family specific primers or ligated primers may be used. The type of constant region 
attached to the variable domain can be determined by immunological marker analysis. 
ad ii) The problems with the amplification of the V-D-J sequence of the IgH gene of 
intermediate and high grade malignant NHL obviate the need for absolute validation of 
the specificity of the generated patient-specific markers. This may be achieved by using 
highly labelled PCR product as a probe for detection of the IgH gene rearrangement on 
Southern blot. 
The solution of these technical problems is a prerequisite for investigating the 
significance of these patient-specific probes as clonal markers in the detection of 
minimal residual disease in intermediate and high grade malignant NHL in a prospective 
study. Even then, the possibility exists that with the generated patient-specific clonal 
marker, residual NHL cells may be missed because of clonal selection of the tumor. 
NHL cells may be in the stage of differentiation in which hypermutation of the Ig alleles 
takes place to select cells that make antibodies with a higher avidity. This phenomenon 
is known to occur in follicular NHL and may also take place in other histological 
subtypes of NHL (50,52-55). To overcome the problem of clonal selection, 
characterization of the NHL clone by more than one clone-specific marker, for instance 
the rearranged immunoglobulin heavy and light chain alleles or t(14;18), which is 
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present in 20% to 30% of these NHL, may be used (5,56,57). In spite of the problems 
mentioned in generating patient-specific clonal markers with peR in intermediate and 
high grade malignant NHL, the possibility to use these markers in the study of minimal 
residual disease in B-cell neoplasms and the clinical relevance justifies further 
investigations. 
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SUMMARY 
In this thesis a new method to detect low numbers of t(14;18)-positive cells, the 
polymerase chain reaction (peR), is used to evaluate the presence of t{14;181-positive 
cells in peripheral blood or bone marrow of patients with t(14;18)~positive follicular 
non~Hodgkin's lymphoma (NHL) in staging at diagnosis and in monitoring the response 
to therapy. 
In chapter 1, we describe clinical and phenotypical aspects of follicular NHL, the most 
common type of NHL. This type of NHL is associated with a specific chromosomal 
translocation, the translocation between chromosomes 14q32 and 18q21 [t(14;18)]. 
The molecular characteristics of the translocation allow the application of the sensitive 
peR, an in vitro DNA amplification technique, for the detection of minimal (residual) 
disease with greater sensitivity in comparison to more conventional techniques such as 
imaging techniques, cytogenetic analysis, morphological examination and 
immunological marker analysis. Application of peR increases the sensitivity with which 
lymphoma cells can be detected approximately 100 to 1000 times. This may be of 
importance in staging the disease at diagnosis and monitoring the disease after therapy. 
In chapter 2 we used the PCR technique to evaluate the presence of t(14;18)-positive 
cells in peripheral blood or bone marrow from patients with predominantly follicular 
centroblastic centrocytic NHl. The peR results were compared with the results of two 
other techniques which were used to detect NHL cells, immunological marker analysis 
and morphologic examination. The peR results were also combined with the clinical 
status of the patient (stage at diagnosis and remission status after therapy) which was 
established by imaging techniques (X-ray photography and CT scanning). Translocation 
{14;1S)-positive cells were demonstrated in peripheral blood or bone marrow using peR 
whereas with immunological marker analysis and morphlogical examination no NHL 
could be detected. In addition, t(14;18)-positive cells were detected in peripheral blood 
or bone marrow of patients without clinical evidence of disease after therapy. 
Therefore, peR appears to be a powerful technique to study minimal residual disease. 
In chapter 3 we used the PCR technique to study the presence of t(14;18)-positive 
cells in peripheral blood or bone marrow of patients with localized (stages I and II) 
t(14;18)-positive follicular NHL We found t(14;18)-positive cells in peripheral blood or 
bone marrow in 75% of these patients. Local therapy does not eradicate these 
t{14;1S)-positive cells in most of the patients. These results support the notion that 
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follicular NHL is in general a disseminated disease regardless clinical staging. 
Chapter 4 describes a longitudinal study to investigate the presence of t(14; 18}-positive 
cells in peripheral blood or bone marrow of patients with disseminated (stages III and 
IV) t(14;18)-positive follicular NHL during first remission obtained by conventional 
therapy. We found no obvious correlation between the presence or absence of 
t(14;18}-positive cells in peripheral blood or bone marrow and i) the remission status 
and ii) the remission duration. Notably, there was a tendency that PCR detectable 
t(14;18)-positive cells were either continuously present or absent in the peripheral 
blood or bone marrow during remission in individual patients. 
In chapter 5 we investigated characteristics of lymphoma cells in patients with NHL 
localized in the testis. These NHL are relatively rare. NHL may disseminate to the testis 
or testicular NHL may occur as a primary manifestation. NHL with testicular localization 
metastasizes preferentially to specific sites. We investigated whether t(14;18) was 
present in this type of NHL To detect the t(14;18) we used cytogenetic analysis, 
Southern blotting and PCR analysis. The BCL·2 gene is involved in t(14;18) and 
therefore we used immunohistochemistry to investigate the presence of the BCL-2 
protein. We found that the BCL-2 protein was present in all lymphomas tested, but that 
t(14;18) was absent in all cases. We suggest that the presence of the BCL-2 protein in 
these lymphomas is related to the differentiation stage of the B-Iymphocyte and/or may 
play a role in the pathogenesis of these lymphomas. The consistent presence of the 
BCL-2 protein without a t{14;18) may support the clinical observation that these NHL 
are a separate entity. 
In chapter 6 we studied the genomiC organization in a newly generated cell line 
containing the chromosomal translocations (8;14) and (14;18). We established the 
localization of the breakpoints on chromosome 8, 14 and 18. Both immunoglobulin 
heavy chain (lgH) genes located on chromosome 14 were disrupted by these two 
translocations. The breakpoint on chromosome 1 S was in the major breakpoint region 
of the BCL-2 gene. The breakpoint on chromosome 8 was located in exon 1 or intron 1 
of the MYC gene. The BCL-2 protein and normal BCL-2 mRNA transcripts were 
detected in the cell line. In contrast, the MYC mRNA was approximately 0.4 kb shorter 
than usual. As can be expected the cells did not express immunoglobulins in the 
cytoplasm or on the cell surface. The cell line may be useful for further studies aimed 
at the involvement of these translocations in deregulating cell growth and maturation. 
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In chapter 7 the clinical value of the detection of t(14;1S)-positive cells in the peripheral 
blood or bone marrow by peR in patients with t(14;18)-positive NHL is discussed. The 
detection of t(14;18)-positive cells by peR is only indicative for the presence of 
lymphoma cells if has been established that t(14;18) is a clonal marker for the 
lymphoma. The clinical value of the detection of t(14;18)-positive cells by peR is 
limited in patients treated with conventional therapy. In these patients we did not found 
a correlation between the presence of t( 1 4; 1 8)-positive cells in peripheral blood or bone 
marrow and i) the stage of disease, ii) remission status and iii) remission duration. 
However, in patients treated with high dose therapy and ABMT, the presence of 
t(14;1 S)-positive cells in the bone marrow after transplantation may possibly predict 
relapse. Thus, the peR method can be useful to monitor the disease when therapy 
modalities are aimed at cure. To extent the applicability of peR based detection 
methods, we started to use the unique immunoglobulin heavy chain gene 
rearrangement in NHL as a patient-specific clonal marker for the malignant cells. In 
spite of technical problems in generating patient-specific clonal markers by peR, the 
possibilities to use these markers in the study of minimal (residual) disease in B-cell 
neoplasms and their clinical relevance, especially in patients with intermediate and high 
grade malignant lymphomas, justifies further investigations. 
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SAMENVATTING 
In dit proefschrift maken wij gebruik van een nieuwe methode om kleine aantallen 
t(14;1S)~positieve cellen te kunnen detecteren, namelijk de polymerase ketting reactie 
(peR). Wij evalueerden de aanwezigheid van t(14;18)-positieve cellen in het bloed of 
beenmerg van patienten met een t(14;18)-positief folliculair non-Hodgkin Iymfoom 
(NHL) tijdens stagering van de ziekte bij diagnose en tijdens het verloop van deze ziekte 
na behandeling. 
In hoofdstuk 1 beschrijven wij klinische en fenotypische aspecten van het meest 
voorkomende NHL namelijk het folliculaire NHL. Oit type NHL is geassocieerd met een 
specifieke chromosoom translocatie, namelijk een translocatie tussen de chromosomen 
14q32 en 18q21 [t(14;18)]. Oe moleculaire karakteristieken van deze translocatie 
maken de toepassing van de gevoelige peR techniek, een in vitro DNA amplificatie 
techniek, mogelijk. Door toe passing van peR kan minimale ziekte met een gratere 
gevoeligheid ten opzichte van de meer conventionele technieken zoals beeldtechnieken, 
cytogenetische, morfologische en immunologische technieken opgespoord worden. De 
gevoeligheid waarmee Iymfoom cellen opgespoord kunnen worden, is door toe passing 
van de peR techniek met een factor 100 tot 1000 toegenomen. Oit kan van be lang zijn 
voor de stagering van de ziekte bij diagnose en voor het vervolgen van de ziekte na 
behandeling. 
In hoofdstuk 2 gebruikten wij de peR techniek om de aanwezigheid van t(14;18)-
positieve cellen in het bloed of beenmerg van voornamelijk patienten met een folliculair 
centroblastisch centrocytisch NHL te evalueren. De peR resultaten werden vergeleken 
met de resultaten verkregen door immunologische en morfologische analyse van het 
bloed of beenmerg. De PCR resultaten werden tevens gecombineerd met de kJinische 
status van de patient zoals vastgesteld door middel van rontgenfoto's en CT scans. 
Translocatie (14; 18)-positieve cellen werden met behulp van de PCR techniek gevonden 
in het bloed en beenmerg terwijl er geen Iymfoom cell en aangetoond konden worden 
met behulp van immuno!ogische en morfologische analyses. In het bloed en beenmerg 
van patienten zonder klinisch aantoonbare ziekte werden ook t(14;18)-positieve cell en 
aangetoond. Dus de PCR techniek is een krachtige techniek waarmee minimale ziekte 
bestudeerd kan worden. 
In hoofdstuk 3 hebben we de peR techniek gebruikt om de aanwezigheid van t(14;18)-
positieve cellen in bloed of beenmerg van patienten met een gelokaliseerd (stadia I en II) 
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t( 14; 18)-positief folliculair NHL te bestuderen. Wij toonden t(14; 18)-positieve cellen aan 
in het bloed of beenmerg van 75% van deze patienten. In de meeste patienten werden 
deze t(14;1 8)~positieve cell en door lakale therapie niet uitgeroeid. Dus in een groot deel 
van de patienten met een foiliculair NHL werden t(14; 18)~posjtieve cellen gevonden in 
het bleed en beenmerg, onafhankelijk van het stadium van de ziekte. 
Hoofdstuk 4 beschrijft een longitudinale studie waarin de aanwezigheid van Iymfoma 
cellen in bloed of beenmerg van patienten met een uitgezaaid (stadia III en IV) t(14;18)-
positief folliculair NHL tijdens de eerste remissie na conventionele behandeling 
bestudeerd werd. Wij venden geen duidelijke relatie tussen de aanwezigheid of 
afwezigheid van t(14;18)-positieve cell en in bleed of beenmerg en i) de mate van de 
remissie en ii) de duur van de remissie. Opmerkelijk is de tendens dat de met behulp 
van PCR aan te tonen t(14;18)-positieve cellen continue aanwezig of afwezig waren in 
bloed of beenmerg tijdens remissie bij individuele patienten. 
In hoofdstuk 5 werden de karakteristieken van NHL met testiculaire localisatie 
bestudeerd. Deze NHL zijn relatief zeldzaam. Deze NHL kunnen zich verspreiden naar de 
testis of ontstaan primair in de testis. Testiculaire NHL verspreiden met voorkeur naar 
specifieke plaatsen. Wij onderzochten of t(14;18) aangetoond kon worden in dit type 
NHL. Om t{14;18) aan te tonen hebben we gebruik gemaakt van cytogenetica, 
Southern blot en PCR analyses. Het BCL-2 gen is betrokken in de t(14;18) en daarom 
hebben wij immunohistochemie gebruikt om de aanwezigheid van het BCL-2 eiwit aan 
te tonen. Het BCL-2 eiwit kon aangetoond worden in aile geteste Iymfomen, dit in 
tegenstelling tot de t(14;18). Wij denken dat de aanwezigheid van het BCL-2 eiwit in 
deze Iymfomen gerelateerd is aan het ontwikkelingsstadium van de B-Iymfocyt en/of 
beJangrijk is in de pathogenese van deze Jymfomen. De aanwezigheid van het BCL-2 
eiwit en de afwezigheid van de t(14;18) ondersteunen de klinische aanwijzingen dat 
deze Iymfomen een aparte identiteit bezitten. 
In hoofdstuk 6 bestudeerden wij de genomische organisatie van een nieuw 
gegenereerde cellijn met de chromosoom translocaties (8; 14) en (14; 18). We bepaalden 
de localisatie van de breukpunten op chromosoom 8, 14 en 18. Beide zware 
immunoglobuline keten genen, gelegen op chromosoom 14, waren onderbroken door 
deze twee translocaties. Het breekpunt op chromosoom 18 was gelegen in een 
specifiek breekpunt gebied van het BCL-2 gen. Het breekpunt op chromosoom 8 was 
gelegen in exon 1 of intron 1 van het MYC gen. Het BCL-2 eiwit en de normale BCL-2 
mRNA transcripten werden gevonden in deze cellijn. Het MYC mRNA was ongeveer 0,4 
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kb korter dan normaal. Ooordat beide zware immunoglobuline keten genen betrokken 
waren in de translokaties werd geen expressie van immunoglobulines in het cytoplasma 
en op de celwand gevonden. De cellijn kan een bijdrage leveren aan het verbeteren van 
het inzicht in de rol van deze translocaties bij de deregulering van celgroei en maturatie. 
In hoofdstuk 7 wordt het klinische belang van het aantonen van kleine aantallen 
t(14;18)-positieve cellen met behulp van PCR in patienten met een t(14;18)-positief 
NHL bediscuseerd. Het opsporen van t(14;18)-positieve cellen met behulp van PCR 
wijst aileen op de aanwezigheid van Iymfoom cellen als de t(14;18) een klonale merker 
is voor het Iymfoom. De klinische waarde van het aantonen van kleine aantallen 
t(14;18}-positieve cellen bij patienten behandeld met conventionele therapie is beperkt. 
Bij deze patienten werd geen relatie gevonden tussen de aanwezjgheid van t(14;18)-
positieve cellen in het bloed of beenmerg en i) het stadium van de ziekte, ii) de mate 
van de remissie en iii) de duur van de remissie. Echter bij patienten behandeld met een 
beenmergtransplantatie is mogelijk wei een relatie gevonden tussen de aanwezigheid 
van t(14;18)-positieve cellen in het beenmerg na transplantatie en de voorspelling van 
een recidief. Vanwege deze mogelijke voorspellende waarde is PCR vooral belangrijk 
voor het vervolgen van de ziekte als de behandeling gericht is op genezing. Om PCR 
detectie methoden algemener te kunnen toepassen zijn wij gestart met het gebruiken 
van het unieke zware immunoglobuline keten gen als een patient-specifieke klonale 
merker voor maligne cellen. Ondanks technische problemen is verder onderzoek 
gerechtvaardigd door de mogelijkhden die deze merkers kunnen hebben voor het 
onderzoek naar minima Ie ziekte in 8-cel maligniteiten, met name non-Hodgkin's 
Iymfomen van de intermediaire en hoge maligniteits graad en hun klinische relevantie. 
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